WO2019175635A1 - Novel whole-cell biocatalyst for the production of trehalulose - Google Patents
Novel whole-cell biocatalyst for the production of trehalulose Download PDFInfo
- Publication number
- WO2019175635A1 WO2019175635A1 PCT/IB2018/051736 IB2018051736W WO2019175635A1 WO 2019175635 A1 WO2019175635 A1 WO 2019175635A1 IB 2018051736 W IB2018051736 W IB 2018051736W WO 2019175635 A1 WO2019175635 A1 WO 2019175635A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sucrose
- gene
- recombinant
- host cell
- cells
- Prior art date
Links
- SVBWNHOBPFJIRU-UHFFFAOYSA-N 1-O-alpha-D-Glucopyranosyl-D-fructose Natural products OC1C(O)C(O)C(CO)OC1OCC1(O)C(O)C(O)C(O)CO1 SVBWNHOBPFJIRU-UHFFFAOYSA-N 0.000 title claims abstract description 66
- NMXLJRHBJVMYPD-IPFGBZKGSA-N trehalulose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O)CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NMXLJRHBJVMYPD-IPFGBZKGSA-N 0.000 title claims abstract description 66
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 29
- 102000004190 Enzymes Human genes 0.000 title abstract description 67
- 108090000790 Enzymes Proteins 0.000 title abstract description 67
- 239000011942 biocatalyst Substances 0.000 title abstract description 32
- 210000004027 cell Anatomy 0.000 claims abstract description 191
- 239000005720 sucrose Substances 0.000 claims abstract description 142
- 229930006000 Sucrose Natural products 0.000 claims abstract description 133
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 132
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 99
- 230000014509 gene expression Effects 0.000 claims abstract description 82
- 108010047540 sucrose isomerase Proteins 0.000 claims abstract description 78
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 38
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 59
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 59
- 230000001939 inductive effect Effects 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 40
- 239000003550 marker Substances 0.000 claims description 23
- 108020001507 fusion proteins Proteins 0.000 claims description 22
- 102000037865 fusion proteins Human genes 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 20
- 101150014136 SUC2 gene Proteins 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 17
- 108091006243 SLC7A13 Proteins 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 239000001963 growth medium Substances 0.000 claims description 11
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 10
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 101150021474 AGT1 gene Proteins 0.000 claims description 9
- 238000011161 development Methods 0.000 claims description 9
- 230000001747 exhibiting effect Effects 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 230000003301 hydrolyzing effect Effects 0.000 claims description 8
- 108700007698 Genetic Terminator Regions Proteins 0.000 claims description 6
- 229960000723 ampicillin Drugs 0.000 claims description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 claims description 4
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 claims description 4
- 108010035235 Phleomycins Proteins 0.000 claims description 4
- 108020005091 Replication Origin Proteins 0.000 claims description 4
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229930027917 kanamycin Natural products 0.000 claims description 2
- 229960000318 kanamycin Drugs 0.000 claims description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
- 229930182823 kanamycin A Natural products 0.000 claims description 2
- 101150006914 TRP1 gene Proteins 0.000 claims 1
- 101150050575 URA3 gene Proteins 0.000 claims 1
- 210000002230 centromere Anatomy 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 230000037430 deletion Effects 0.000 abstract description 22
- 238000012217 deletion Methods 0.000 abstract description 19
- 108010051210 beta-Fructofuranosidase Proteins 0.000 abstract description 17
- 239000001573 invertase Substances 0.000 abstract description 16
- 235000011073 invertase Nutrition 0.000 abstract description 16
- 238000006243 chemical reaction Methods 0.000 abstract description 10
- 239000000047 product Substances 0.000 description 34
- 239000013612 plasmid Substances 0.000 description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 27
- 239000000758 substrate Substances 0.000 description 27
- 239000008103 glucose Substances 0.000 description 26
- 238000000855 fermentation Methods 0.000 description 20
- 230000004151 fermentation Effects 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- 229930091371 Fructose Natural products 0.000 description 16
- 239000005715 Fructose Substances 0.000 description 16
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 15
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 102100026842 Serine-pyruvate aminotransferase Human genes 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 230000012010 growth Effects 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 210000005253 yeast cell Anatomy 0.000 description 12
- 108700026244 Open Reading Frames Proteins 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 10
- 230000007062 hydrolysis Effects 0.000 description 10
- 238000006460 hydrolysis reaction Methods 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 108090000769 Isomerases Proteins 0.000 description 9
- 102000004195 Isomerases Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 238000003119 immunoblot Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 238000009835 boiling Methods 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000006911 enzymatic reaction Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000035484 reaction time Effects 0.000 description 7
- 150000003445 sucroses Chemical class 0.000 description 7
- 229940035893 uracil Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 241000083686 [Pseudomonas] mesoacidophila Species 0.000 description 5
- FXAGBTBXSJBNMD-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FXAGBTBXSJBNMD-UHFFFAOYSA-N 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 238000001952 enzyme assay Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 101150094690 GAL1 gene Proteins 0.000 description 4
- 102100028501 Galanin peptides Human genes 0.000 description 4
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 4
- 101100001142 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AGA2 gene Proteins 0.000 description 4
- 239000008351 acetate buffer Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 4
- 239000001639 calcium acetate Substances 0.000 description 4
- 229960005147 calcium acetate Drugs 0.000 description 4
- 235000011092 calcium acetate Nutrition 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 102000003673 Symporters Human genes 0.000 description 3
- 108090000088 Symporters Proteins 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 238000011143 downstream manufacturing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000008494 α-glucosides Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 238000000116 DAPI staining Methods 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000021092 sugar substitutes Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 108091036333 Rapid DNA Proteins 0.000 description 1
- 101100001141 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AGA1 gene Proteins 0.000 description 1
- 108010052160 Site-specific recombinase Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710117283 Sucrose permease Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000012122 aqueous mounting media Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 102000043871 biotin binding protein Human genes 0.000 description 1
- 108700021042 biotin binding protein Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000001152 differential interference contrast microscopy Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 230000009643 growth defect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010963 scalable process Methods 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/24—Preparation of compounds containing saccharide radicals produced by the action of an isomerase, e.g. fructose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2431—Beta-fructofuranosidase (3.2.1.26), i.e. invertase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/12—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01026—Beta-fructofuranosidase (3.2.1.26), i.e. invertase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y504/00—Intramolecular transferases (5.4)
- C12Y504/99—Intramolecular transferases (5.4) transferring other groups (5.4.99)
- C12Y504/99011—Isomaltulose synthase (5.4.99.11)
Definitions
- the present invention pertains to the field of enzyme engineering. More particularly, the invention relates to a novel whole cell biocatalyst for production of trehalulose from sucrose and the process for development thereof.
- Trehalulose (a-D-glucosylpyranosyl-l,l-D fmctofuranose) is a structural isomer of sucrose which is composed of glucose and fructose joined by an alpha (1-1) glycosidic bond. It is naturally present in honey in very low quantities. In addition to sweetness, trehalulose shows physical and organoleptic characteristics that are very similar to sucrose. Further, trehalulose is non-cariogenic, has low glycemic index and is a low-insulinemic sugar. Absence of toxicity, mutagenicity and other side effects makes trehalulose a suitable substitute for sugar in various foods and beverages. Trehalulose has been reported to be suitable for consumption by public.
- Enzymatic bioconversion is a preferred method for the production of trehalulose because of the complexity in its chemical synthesis.
- sucrose isomerase activity The current methods used for conversion of sucrose into isomers, particularly trehalulose by using sucrose isomerase activity involves following approaches:
- sucrose isomerase production of sucrose isomerase in recombinant host
- the inventors have identified the above issues and addressed the same by employing a multidimensional approach wherein recombinant yeast strains have been created by inactivating sucrose hydrolyzing genes in a host cell combined with the expression of sucrose isomerase on the surface of the host by way of fusion protein.
- the host organism In the absence of SUC2 and AGT1 gene, the host organism is unable to utilize the disaccharide sucrose for metabolism. Subsequently, the yield of trehalulose is high and the downstream processing cost is low.
- the present invention thus addressed the drawbacks of existing approaches to solve a long-standing problem of providing an efficient, cheap and industrially-scalable means for production of trehalulose.
- the present invention relates to a novel whole cell biocatalyst for production of trehalulose from sucrose.
- the recombinant biocatalyst has been developed by deletion of SUC2 and AGT1 encoding genes, which are responsible for hydrolyzing sucrose in a host cell combined with the expression of sucrose isomerase on the surface of the host by way of fusion protein.
- the biocatalyst shows dramatic decrease in utilization of the disaccharide sucrose for metabolism.
- the sucrose remained available for the bioconversion in to trehalulose and the recombinant cells exhibits a high rate of bioconversion.
- the invention discloses a modified open reading frame encoding for sucrose isomerase enzyme fused to the C-terminus of GPI anchor protein.
- the invention also discloses vectors comprising the modified open reading frame under the control of constitutive or inducible promoter.
- the invention provides for a fusion protein which is a sucrose isomerase enzyme fused to C-terminus of a cell surface anchor protein.
- the invention also provides for an efficient bioconversion process for production of trehalulose using the recombinant biocatalyst.
- the one-step production process can be performed under a wide range of physical and chemical conditions to obtain optimum yield of trehalulose.
- the biocatalyst used in the process is reusable and provides for efficient and cheap downstream processing.
- Fig. 1 shows the vector map of recombinant plasmid pGH-SI_R3 which shows the gene construction for constitutive expression of recombinant fusion protein.
- Fig. 2 shows the vector map of recombinant plasmid pGL-SI_R3 which shows the gene construction for inducible expression of recombinant fusion protein.
- Fig. 3 shows the sucrose and residual sugars after growth of wild type strains (shown as wild type) and modified strains (shown as NY -EM2 and NY -YM2) in the presence of synthetic growth media containing sucrose, glucose and fructose.
- Fig. 4 shows the residual sucrose after growth of wild type strains compared with NY- EM2 and NY-YM2 strains in synthetic growth media containing 20 g/L sucrose, 20 g/L sucrose supplemented with 20 g/L glucose or 20 g/L sucrose supplemented with 20 g/L fructose.
- Lig. 5 shows the residual invertase activity of NY -EM2 and NY -YM2 strains compared to respective wild type strains.
- Lig. 6 shows the microscopy of immunofluorescence-labeled recombinant yeast cells.
- Lig. 7 shows the expression profile of cell surface displayed sucrose isomerase by immunoblot analysis from different fractions of cell lysate from constitutive and inducible expression strains compared with the native strains.
- Lig. 8 shows the fermentation kinetics and cell surface displayed sucrose isomerase activity by recombinant constitutive expression strain NY-YM2 (pGH-SI_R3).
- Lig. 9 shows the fermentation kinetics and cell surface displayed sucrose isomerase activity by recombinant inducible expression strain NY-EM2 (pGL-SI_R3).
- Lig. 10 shows the expression profile of CSD-SIase by immunoblot analysis from samples collected from constitutive [NY-YM2 (pGH-SI)] and inducible expression [NY-EM2 (pGL-SI)] strains at different fermentation time points.
- Lig. 11 shows the product formation kinetics using different amount of CSD-SIase cells.
- Lig. 12 shows the product formation kinetics using different amount of sucrose as substrate with CSD-SIase.
- Lig. 13 shows the chromatogram of samples after bioconversion of sucrose into trehalulose by recombinant strains constitutively producing CSD-SIase.
- Lig. 14 shows the bioconversion kinetics of CSD-SIase produced by constitutive expression strain [NY-YM2 (pGH-SI)].
- Fig. 15 shows the bioconversion kinetics of CSD-SIase produced by inducible expression strain [NY-EM2 (pGL-SI)].
- Fig. 16 shows the temperature optima profiles of CSD-SIase and native Slase.
- Fig. 17 shows the pH profiles of CSD-SIase and native Slase.
- Fig. 18 shows the residual activity of CSD-SIase enzymes compared to native Slase enzyme.
- the present invention discloses a genetically modified host cell, which can be used as a whole cell biocatalyst for the production of trehalulose from sucrose.
- the invention contemplates a multidimensional approach for achieving a high rate of bioconversion of sucrose into trehalulose using a whole cell biocatalyst.
- the biocatalyst created for efficient, cheap and industrially scalable bioconversion of sucrose to trehalulose is characterized by the following:
- sucrose hvdrolvzation - Sucrose is utilized by a large array of host organisms for metabolism. Therefore, most of the sucrose present in the substrate is utilized by the host organism and is not available for bioconversion.
- the present invention overcomes this issue.
- host cell includes an individual cell or cell culture which can be, or has been, a recipient for the subject of expression constructs.
- Host cells include progeny of a single host cell.
- Host cell can be any expression host including prokaryotic cell such as but not limited to Escherichia coli, Bacillus subtilis, Pseudomonas putida, Corynebacterium glutamicum or eukaryotic system, such as, but not limited to Saccharomyces cerevisiae, Pichia pastoris, Hansenula polymorpha.
- recombinant strain refers to a host cell which has been transfected or transformed with the expression constructs or vectors of this invention.
- expression cassette denotes a gene sequence used for cloning in expression vectors or in to integration vectors or integrated in to coding or noncoding regions of chromosome of the host cell in a single or multiple copy numbers, where the expression cassette directs the host cell's machinery to make RNA and protein encoded by the expression cassette.
- expression construct is used here to refer to a functional unit that is built in a vector for the purpose of expressing recombinant proteins/peptides, when introduced into an appropriate host cell, can be transcribed and translated into a fusion protein which is displayed on the cell wall.
- promoter refers a DNA sequences that define where transcription of a gene begins. Promoter sequences are typically located directly upstream or at the 5' end of the transcription initiation site. RNA polymerase and the necessary transcription factors bind to the promoter sequence and initiate transcription.
- constitutive promoter is more commonly defined the promoter which allows continual transcription of its associated genes as their expression is normally not conditioned by environmental and developmental factors. Constitutive promoters are very useful tool in genetic engineering because constitutive promoters drive gene expression under inducer-free conditions and often show better characteristics than commonly used inducible promoters.
- inducible promoter refers the promoters that are induced by the presence or absence of biotic or abiotic and chemical or physical factors. Inducible promoters are a very powerful tool in genetic engineering because the expression of genes operably linked to them can be turned on or off at certain stages of development or growth of an organism or in a particular tissue or cells.
- RNA messenger RNA
- translation refers the process of translating the sequence of a messenger RNA (mRNA) molecule to a sequence of amino acids during protein synthesis.
- mRNA messenger RNA
- the genetic code describes the relationship between the sequence of base pairs in a gene and the corresponding amino acid sequence that it encodes.
- the ribosome reads the sequence of the mRNA in groups of three bases to assemble the protein.
- terminal sequence refers to a nucleotide sequence that is required for the termination reaction of the transcription process. Termination involves recognition of the point at which no further bases should be added to a growing RNA chain.
- fusion protein refers to a polypeptide which comprises protein domains from at least two different proteins.
- the fusion protein is sucrose isomerase fused to C- terminus of a cell surface anchor protein.
- sucrose hydrolyzing genes refers to genes which are responsible for sucrose hydrolysis.
- sucrose hydrolyzing genes refers to SUC2 invertase and AGT1 alpha-glucoside transporter.
- inducible excision system refers to site-specific recombinase technologies which can be used for efficiently regulating the excision or deletion of genes.
- the inducible excision system employed in the invention is cre-lox excision system.
- replication origin refers to the site on a nucleic acid sequence at which replication is initiated. Bacterial or yeast replication origins may be required in a recombinant vector for significant expression of the desired polypeptide.
- selection marker gene refers to a gene determinant that, when expressed in the cell, confers a specific set of characteristics upon the cell that allows such a cell to be distinguished, or selected out, from other cells not carrying or expressing said gene determinant.
- anchor protein or "cell surface anchor protein” is used to describe proteins or peptides which are anchored to the external surface of the plasma membrane generally by covalent bonding to glycans containing phosphatidyl inositol.
- the structures to which the anchor protein or peptide is bonded are often referred to as glycosylphosphatidylinositol or GPIs.
- GPIs glycosylphosphatidylinositol
- anchor proteins covalently bonded to GPIs are found on the external face of the plasma membrane of cells or on the lumenal surface of secretory vesicles.
- the anchor protein is a GPI anchor protein, AGA2 which is fused in frame to the N-terminus of sucrose isomerase.
- modified sucrose isomerase is used to refer to a fusion protein containing GPI anchor protein such as AGA2 fused in frame to the N-terminus of sucrose isomerase.
- GPI anchor protein such as AGA2 fused in frame to the N-terminus of sucrose isomerase.
- the N- terminus region of the fusion protein will anchor to the cell surface of the host cell and display the free sucrose isomerase over the cell wall for bioconversion of sucrose into trehalulose.
- specific activity is defined as the micromoles of product formed per minute per milligram of enzyme.
- NY-YM denotes the wild type yeast strain ATCC 208352 and“NY-YM2” denotes the modified yeast strain after deletion of invertase (SUC2) and symporter (AGT1) genes.
- SUC2 invertase
- AGT1 symporter
- NY-EM strain denotes the wild type yeast strain ATCC 208289 and“NY-EM2” denotes the modified yeast strain after deletion of invertase (SUC2) and symporter (AGT1) genes.
- SUC2 invertase
- AGT1 symporter
- GPI-SI nucleotide sequence designates fusion protein of sucrose isomerase fused in frame with cell surface anchor protein.
- NY-YM2 pGH-SI_R3 designates the final transformed yeast strain having the artificially synthesized gene encoding for sucrose isomerase of Pseudomonas mesoacidophila under constitutive promoter control.
- NY-EM2 (pGL-SI_R3) designates the final transformed yeast strain having the artificially synthesized gene encoding for sucrose isomerase of Pseudomonas mesoacidophila under inducible promoter control.
- the present invention discloses novel whole cell biocatalysts for production of trehalulose from sucrose and the process for development thereof. Further, the invention also nucleic acids which encode sucrose isomerase enzyme fused to a cell surface anchor protein. Further, the invention discloses a recombinant cell in which the invertase and sucrose permease encoding genes have been made inoperative, and the recombinant cell has been engineered to display sucrose isomerase enzyme on the cell surface.
- the present invention provides a modified nucleic acid encoding sucrose isomerase gene fused in frame with cell surface anchor proteins.
- the modified nucleic acid may employ native genes or synthetic genes optimized as per the codon preference of the host organism.
- the modified nucleic acid is the nucleic acid encoding for sucrose isomerase (Slase) of Pseudomonas mesoacidophila, fused in frame with cell surface anchor proteins, such as, but not limited to GPI proteins like AGA2 protein.
- Slase sucrose isomerase
- the modified nucleic acid is represented by SEQ ID NO: 1.
- the invention provides for a fusion protein, which was constructed by the cell surface anchor protein of Saccharomyces cerevisiae being fused in-frame with the N- terminus of sucrose isomerase (Slase) of Pseudomonas mesoacidophila MX-45.
- the fusion protein is represented by SEQ ID NO:6.
- the present invention provides a modified expression cassette comprising a promoter, a modified open reading frame encoding for sucrose isomerase enzyme fused to the C-terminus of GPI anchor protein and a terminator sequence.
- the promoter chosen may either be for constitutive expression or for inducible expression.
- the modified expression cassette can express sucrose isomerase on the surface of a wide range of host organisms, such as, but not limited to Saccharomyces cerevisiae.
- the construct carries a constitutive promoter, such as, but not limited to, GAPDH promoter.
- the construct carries an inducible/regulated promoter, such as, but not limited to GAL1, pGALlO, pSUC2, pXYL or pADH promoter.
- an inducible/regulated promoter such as, but not limited to GAL1, pGALlO, pSUC2, pXYL or pADH promoter.
- the expression cassette for constitutive expression comprises the modified nucleic acid represented by SEQ ID NO: l, a GAPDH promoter represented by SEQ ID NO:2 and a GAPDH terminator represented by SEQ ID NO:4.
- the expression cassette for inducible expression comprises the modified nucleic acid represented by SEQ ID NO: l, a GAL1 promoter represented by SEQ ID NOG and a MFa terminator represented by SEQ ID NO: 5.
- the invention provides for expression vectors comprising the expression cassette.
- the modified expression cassettes are cloned into expression vectors for recombinant expression.
- the expression vectors can be used in both prokaryotic as well as eukaryotic organisms.
- the shuttle vector used provides for a number of selectable markers such as, but not limited to, ampicillin resistance marker, uracil selectable marker or tryptophan selectable maker.
- the vector also comprises of bacterial origin of replication, 2m for replication in yeast or CEN for replication in yeast.
- the expression vector for constitutive expression is a pYEP plasmid, more specifically a pGH plasmid.
- the recombinant plasmid contains the open reading frame, a constitutive GAPDH promoter, GAPDH terminator, ampicillin resistance marker for bacterial selection, pBR322 for bacterial origin of replication, URA (uracil) auxotrophic markers for selection in yeast and 2m for replication in yeast.
- the modified sequence encoding for the fusion protein was cloned in to pGH yeast expression vector using Nhel and Xhol sites in frame with GPI anchor which is under control of constitutive promoter yielding pGH_GPI-SI_R3 (also referred to as pGH-SI_R3).
- GPI-sucrose isomerase (GPI-SI) gene in pGH-SI_R3 plasmid is flanked by EcoRI at 5’end and Hindlll at 3’end. Sall and Xhol were lost during the cloning procedure.
- the modified vector is depicted in Figure 1.
- the expression vector for inducible expression is a pRS3 l4 plasmid, more specifically, pGL plasmid.
- the recombinant plasmid contains an inducible promoter, MFa (Alpha-factor) terminator, Ampicillin resistance marker for bacterial selection, fl for bacterial origin of replication, TRP (tryptophan) auxotrophic markers for selection in yeast and CEN for replication in yeast.
- the modified sequence was cloned in to pGL yeast expression vector using Nhel and Bam HI sites in frame with GPI anchor which is under control of inducible promoter yielding pGL_GPI-SI_R3 (also referred to as pGL-SI_R3).
- GPI-sucrose isomerase (GPI-SI) gene in pGL-SI_R3 plasmid is flanked by EcoRI at 5’end, and BamHI at 3’end.
- the modified vector is depicted in Figure 2.
- the invention provides host cells in which sucrose hydrolyzing genes have been inactivated by knock-out or deletion.
- the invention provides yeast strains which lacks expression of both SUC2 invertase and AGT1 alpha-glucoside transporter.
- the strains are characterized by extremely low sucrose hydrolysis ability. Therefore, the problem of rapid depletion of sucrose due to metabolism of cells is avoided and the complete substrate is available for bioconversion to desirable products by cell surface display of recombinant enzymes.
- the deletion of genes encoding for SUC2 and AGT1 in the host strain is done using an inducible gene excision system, such as, cre-lox system.
- Gene disruption cassettes designed with the heterologous dominant kanamycin resistant marker with a Cre/loxP mediated marker removal procedure is used.
- the loxP-Marker gene-loxP gene disruption cassettes are generated by PCR amplification using pUG6 vector as template. Flanking homology sequences to the AGT1 gene upstream and downstream to the target gene are added to the disruption cassette primers.
- the PCR product was used as a template for further long flanking homology ends using a 2nd set of primers to add more nucleotide sequence for an accurate homologous recombination.
- the amplified products were used as deletion cassettes and transformed into yeast strain, such as, but not limited to, W303-1A or BJ5465 strains.
- yeast strain such as, but not limited to, W303-1A or BJ5465 strains.
- the invention provides for engineered strain which can grow in media with glucose or fructose. But the engineered strains show severe growth defect when grown in media with sucrose alone.
- sucrose hydrolysis is dramatically decreased in engineered strains compared to their wild type strains. Additionally, the engineered strains NY-EM2 and NY-YM2 hydrolyzes sucrose very slowly in the presence of additional glucose or fructose in growth media when compared to its wild type strains.
- the invention provides for the development of recombinant host cells.
- the recombinant plasmids encoding a cell surface anchor protein of Saccharomyces cerevisiae being fused in-frame with the N-terminus of sucrose isomerase (Slase) of Pseudomonas mesoacidophila are transformed into a yeast host strains which lacks both SUC2 invertase and AGT1 alpha-glucoside transporter to create a whole cell biocatalyst with a high rate of bioconversion.
- the biocatalyst shows dramatic decrease in utilization of the disaccharide sucrose for metabolism.
- the sucrose remained available for the bioconversion in to trehalulose and the recombinant cells exhibits a high rate of bioconversion.
- the engineered strain may also contain additional modifications for preproduction of AGA1 protein under control of GAL1 promoter and/or deletion of major Pir (Pir 1-3) proteins for enhanced display of cell surface anchor proteins.
- the invention relates to recombinant host cell which has been developed by deletion of SUC2 and AGT1 encoding genes in a host cell combined with the expression of sucrose isomerase on the surface of the host by way of fusion protein.
- the recombinant host cell has been engineered for constitutive expression.
- the cells were treated to prepare electrocompetent cells.
- the recombinant plasmids pGH-SI_R3 were transformed in to electrocompetent cells by standard electroporation method.
- the strains transformed with pGH-SI_R3 were selected on SD-Ura plates.
- the invention relates to recombinant host cell which has been developed by deletion of SUC2 and AGT1 encoding genes in a host cell combined with the expression of sucrose isomerase on the surface of the host by way of fusion protein.
- the recombinant host cell has been engineered for inducible expression.
- the cells were treated to prepare electrocompetent cells.
- the recombinant plasmids pGL-SI_R3 were transformed in to electrocompetent cells by standard electroporation method.
- the strains transformed with pGH-SI_R3 were selected on SD-Trp plates.
- the yeast strains used were procured from ATCC (American Type Culture Collection: Global Bioresource Centre) headquartered in Manassas, Virginia, USA.
- ATCC 208352 (Strain Designation: W303-la) has been used to develop MTCC 5985 recombinant host cell for constitutive CSD-SIase expression
- ATCC 208289 (Strain designation: BJ5465) has been used to develop MTCC 5987 recombinant host cell for inducible CSD-SIase expression. Both the strains were deposited on 2lst January, 2015.
- CSD-SIase shows significant bioconversion activity not only at the optimum temperature but even at lower temperatures in the range of l5-40°C as compared to the native enzyme.
- the invention provides that the optimum temperature for CSD sucrose isomerase is in the range of l5°C to 40°C, more precisely 25°C compared to native enzyme which is in the range of l5°C to 40°C, more precisely 30°C.
- a further aspect of the present invention is that the optimum pH for CSD sucrose isomerase is in the range of 4 to 6.5, more precisely 6.2 as compared to native enzyme which is in the range of 5.0 to 6.7, more precisely 6.5.
- the cell surface displayed sucrose isomerase exhibits broader pH tolerance higher than that of the native enzyme.
- the invention provides for an industrially scalable process for production of trehalulose.
- the process includes culturing the recombinant Saccharomyces cerevisiae host cells in defined media.
- the culture medium has pH ranging between 4 to 6.5 and temperature maintained between l5°C to 30°C. Further, the recombinant host cells are contacted with 10% to 45% sucrose solution and trehalulose is harvested from the solution.
- bioconversion depends upon the amount of substrate used.
- the amount of substrate can be increased upto 45% for efficient conversion of sucrose into trehalulose.
- Another aspect of the invention provides that cell surface displayed sucrose isomerase is stable and retains more than 50% of its activity for up to 120 hrs at optimum pH and temperature when compared to native enzyme.
- Example 1 Gene construction for constitutive expression of recombinant fusion protein GPI-SI in Saccharomyces cerevisiae
- sucrose isomerase (SIase) was modified for expression of sucrose isomerase on the surface of Saccharomyces cerevisiae cells.
- the modified gene contains a constitutive promoter, a modified open reading frame encoding for sucrose isomerase enzyme fused to the C-terminus of GPI anchor protein and a terminator sequence.
- the sequence of the modified open reading frame encoding for sucrose isomerase enzyme fused to the C-terminus of GPI anchor protein is represented by SEQ ID NO: 1.
- the constitutive promoter used is GAPDH promoter sequence which is represented by SEQ ID NO: 2.
- the terminator used is a GAPDH terminator which is represented by SEQ ID NO: 4.
- This modified open reading frame has been artificially synthesized by using the sequence for sucrose isomerase of Pseudomonas mesoacidophilaMX-4-5 and the sequence of AGA2 protein from Saccharomyces cerevisiae.
- the plasmid used in the process was a pYEP plasmid, more specifically pGH plasmid.
- the recombinant plasmid contains the open reading frame, a constitutive GAPDH promoter, GAPDH terminator, Ampicillin resistance marker for bacterial selection, pBR322 for bacterial origin of replication, UR A (uracil) auxotrophic markers for selection in yeast and 2m for replication in yeast.
- the modified sequence encoding for the fusion protein was cloned in to pGH yeast expression vector using Nhel and Xhol sites in frame with GPI anchor which is under control of constitutive promoter yielding pGH_GPI-SI_R3(also referred to as pGH-SI_R3).
- the vector map is represented in Figure 1.
- GPI-sucrose isomerase (GPI-SI) gene in pGH-SI_R3 plasmid is flanked by EcoRI at 5’end and Hindlll at 3’end. Sall and Xhol were lost during the cloning procedure. Recombinant plasmids were confirmed by restriction digestion analysis and followed by DNA sequencing.
- Example 2 Gene construction for inducible expression of recombinant fusion protein GPI- SI in Saccharomyces cerevisiae
- sucrose isomerase was modified for expression of sucrose isomerase on the surface of Saccharomyces cerevisiae cells.
- the modified gene contains an inducible promoter, a modified open reading frame encoding for sucrose isomerase fused to the C-terminus of GPI anchor protein and a terminator sequence.
- the sequence of the modified open reading frame encoding for sucrose isomerase enzyme fused to the C-terminus of GPI anchor protein is represented by SEQ ID NO: 1.
- the inducible promoter used is GAL1 promoter sequence which is represented by SEQ ID NO: 3.
- the terminator used is a MFa (Alpha-factor) terminator which is represented by SEQ ID NO: 5.
- the plasmid used in the process was a pRS3l4 plasmid, more specifically pGL plasmid.
- the recombinant plasmid contains an inducible promoter, MFa (Alpha-factor) terminator, Ampicillin resistance marker for bacterial selection, fl for bacterial origin of replication, TRP (tryptophan) auxotrophic markers for selection in yeast and CEN for replication in yeast.
- the modified sequence was cloned in to pGL yeast expression vector using Nhel and Bam HI sites in frame with GPI anchor which is under control of inducible promoter yielding pGL_GPI-SI_R3 (also referred to as pGL-SI_R3).
- the vector map is represented in Figure 2.
- GPI-sucrose isomerase (GPI-SI) gene in pGL-SI_R3 plasmid is flanked by EcoRI at 5’end, and BamHI at 3’end. Recombinant plasmids were confirmed by restriction digestion analysis and followed by DNA sequencing.
- Example 3 Polynucleotide sequence for expression of sucrose isomerase and corresponding polypeptide sequence
- a modified open reading frame represented by SEQ ID NO: 1 was artificially synthesized for encoding a fusion protein wherein a polynucleotide sequence coding for cell surface anchor protein was fused in-frame with a polynucleotide sequence encoding sucrose isomerase (Slase) enzyme.
- Slase sucrose isomerase
- the fusion protein obtained by translating the gene encoding for sucrose isomerase fused to the C-terminus of GPI anchor protein is represented by SEQ ID NO:6.
- the fusion protein is a cell surface anchor protein of Saccharomyces cerevisiae being fused in-frame with the N- terminus of sucrose isomerase (Slase) of Pseudomonas mesoacidophilaMX-4-5.
- Example 4 Development of strain for reduced ability to hydrolyze sucrose by deletion of AGT1 and SUC2 gene
- yeast cells were grown in rich media such as Yeast Extract Peptone Dextrose (YEPD) broth and 50 mL of the yeast cells at log-phase were collected by centrifugation at 2000 g, washed with phosphate buffer twice and resuspended in 1M chilled sorbitol. The cells were washed once in 1M chilled sorbitol, resuspended in 5 mL of chilled sorbitol and used for the electro-transformation with the disruption cassettes for AGT1.
- rich media such as Yeast Extract Peptone Dextrose (YEPD) broth
- 50 mL of the yeast cells at log-phase were collected by centrifugation at 2000 g, washed with phosphate buffer twice and resuspended in 1M chilled sorbitol.
- the cells were washed once in 1M chilled sorbitol, resuspended in 5 mL of chilled sorbitol and used for the electro-transformation with the disruption cassettes for A
- the gene disruption cassette was designed with the heterologous dominant Kan R resistant marker with a Cre/loxP mediated marker removal procedure.
- the loxP-Marker gene-loxP gene disruption cassettes were generated by PCR amplification using pUG6 deletion cassette plasmid as template and primers having flanking homology sequences to the AGT1 gene (30 bp) upstream and downstream to the target gene followed by the sequence homologous to universal loxP-marker amplification sequence.
- the disruption cassette used for deletion of AGT1 gene is represented by SEQ ID NO: 7.
- the amplified PCR product was purified and was reused as template for second PCR amplification and primers having long flanking homology sequences to the AGT1 gene further upstream and downstream to the target gene followed by the sequence homologous to first set of deletion cassette amplification primer sequence.
- the amplified loxP-marker gene-loxP gene disruption cassette with long (60 bp) flanking ends homology to AGT1 gene sequence was purified and were transformed into electrocompetent yeast cells by electroporation using the rapid DNA transformation protocol as described in Methods in Enzymology, Vol 191.
- the transformants were plated on YPD plates containing 200pg/mL G418 and incubated for 4 days at 28°C. Putative transformants obtained were restreaked on YPD agar plated containing 200 pg/mL G418. The transformants were verified by PCR with appropriate primers for confirmation of deletion of the AGT1 gene in the chromosome by comparing the amplified product with the PCR product obtained from the wild type genomic DNA. Among transformants, the strains NY-EM1 and NY-YM1 showed promising results with sucrose uptake studies which is used as host strain for further development.
- SUC2 knockout cassette was designed using loxP flanking end with BLE (phleomycin) marker which confers resistance to phleomycin in yeast for the selection.
- the disruption cassette was PCR amplified using pUG66 deletion cassette plasmid as template and further amplified using the primary PCR product as template for long flanking homology ends with SUC2 upstream and downstream sequences in the primers.
- the disruption cassette used for deletion of SUC2 gene is represented by SEQ ID NO: 8.
- the PCR product was purified and transformed into electrocompetent NY-EM1 and NY- YM1 yeast cells and selected on YEPD plates containing 7.5 pg/mL phleomycin. The transformants were verified by PCR with respective primers for confirmation of deletion of the SUC2 gene in the chromosome and by comparing the amplified product with the PCR product obtained from the wild type genomic DNA.
- the developed double deletion strain was designated as NY -EM2 and NY -YM2.
- Example 5 Sucrose utilization studies by recombinant NY-EM2 and NY-YM2 strains
- the double mutant strains NY -EM2 and NY -YM2 were tested for their ability to grow in media containing sucrose alone or in combination with glucose or fructose.
- the growth profile and the residual sugars present in growth media at different time points were analyzed for utilization of sugars for cell growth and the presence of residual invertase activity for sucrose hydrolysis respectively.
- the mutant strains showed slow growth behavior when grown in sucrose compared to their wild type background due to reduced ability of sucrose uptake and hydrolysis.
- the uptake and utilization of sucrose, glucose and fructose were individually studied.
- the wild type strains and modified strains were grown. Samples were collected at different time points and the availability of residual sucrose, glucose and fructose were analyzed by HPLC analysis with appropriate standards.
- Both NY -YM2 and NY -EM2 strains show dramatic reduction in sucrose hydrolysis when grown on synthetic growth media containing sucrose as carbon source compared to their wild type strains NY-YM and NY-EM, respectively.
- the NY-YM2 strain hydrolyzed only 22% of sucrose. Hence 78% of sucrose remains in the medium after 24hrs incubation whereas the wild type NY-YM hydrolyzed 52% of sucrose. Hence, only 48% of sucrose remains in the medium after 24hrs incubation. This result highlights that the NY-YM2 strain dramatically lost the ability to hydrolyze the sucrose for its growth and the use of this stain makes 30% more sucrose available for bioconversion in to trehalulose by the whole cell biocatalyst.
- the NY-EM2 strain hydrolyzed only 33% of sucrose. Hence, 67% of sucrose remains in the medium after 24hrs incubation.
- the wild type NY-EM hydrolyzed 68% of sucrose and hence, only 32% of sucrose remains in the medium after 24hrs incubation.
- This result highlights that the NY-EM2 strain also dramatically lost the ability to hydrolyze the sucrose for its growth and makes 35% more sucrose available for bioconversion in to trehalulose by sucrose isomerase. The results of this study are depicted in Fig.3.
- sucrose individually and in combination with glucose and fructose was studied.
- Wild type strains (NY-EM and NY-YM) and the recombinant strains (NY-EM2 and NY-YM2) were grown in synthetic growth media containing 20 g/L sucrose alone or 20 g/L sucrose supplemented with 20 g/L glucose or fructose. After 24 hrs of growth the residual sucrose was analyzed by HPLC analysis.
- Both NY-YM2 and NY-EM2 strains show the presence of residual sucrose in the media after 24 hrs of incubation due to their inability to hydrolyze the sucrose, while the wild type strain was found to be hydrolyzing the sucrose completely.
- glucose or fructose hydrolysis products of sucrose
- both NY-YM2 and NY-EM2 strain show better accumulation of sucrose compared to wild type strain.
- This result highlights that the glucose can be used as carbon source for growth of NY -YM2 and NY-EM2 strains for whole cell biocatalyst preparation.
- Glucose can also be used while bioconversion of sucrose in to trehalulose is being done by the recombinant strains.
- NY-YM2 and NY-EM2 strains grow slowly compared to their wild type strains in growth media containing sucrose as sole carbon source due to their inability to hydrolyze sucrose, whereas the growth behavior of NY-YM2 and NY-EM2 stains are similar to wild type strains when grown with glucose.
- the residual invertase activity of NY-EM2 and NY-YM2 strains compared to the respective wild type strains was studied.
- the cells were incubated with 9.5 g/L sucrose in sucrose isomerase assay buffer at 30°C for up to 12 hrs and samples were analyzed for residual sucrose after formation of glucose and fructose (not shown) by action of residual invertase activity.
- the mutant strains were able to grow identical to their wild type strain when grown in presence of glucose or fructose. Sucrose remained unaltered up to 8hrs when incubated with double mutant strains whereas the wild type strain exhibited that sucrose was getting depleted gradually. Approximately 70 - 75 % sucrose remained unaltered when incubated with double mutant strain(s) for 24 - 48 hrs whereas sucrose was completely depleted by wild type strain at similar conditions. Both NY-YM2 and NY-EM2 strains show high amount of residual sucrose in the sucrose isomerase assay buffer at optimum temperature even after 12 hrs of incubation, whereas the sucrose is depleted when incubated with wild type strain due presence of high invertase activity.
- NY-YM2 and NY-EM2 strains are very suitable host strains for the development of recombinant strains for production of cell surface displayed sucrose isomerase, which can be used as whole cell biocatalyst for bioconversion of sucrose in to trehalulose.
- the results of the studies are depicted in Fig.5.
- Example 6 Development of recombinant yeast strains by transformation with recombinant gene constructs
- the strains were grown in YEPD broth and supplemented with 2% glucose and the cells were treated with ice cold sorbitol to prepare electrocompetent cells.
- the recombinant constructs pGH-SI_R3 and pGL-SI_R3 were transformed in to electrocompetent cells by standard electroporation method.
- strains transformed with pGH-SI_R3 were selected on SD-Uraplates and the strains transformed with pGL-SI_R3were selected on SD-Trp or at 30°C.
- Transformed strains NY-YM(pGH-SI_R3), NY- YM2 (pGH-SI_R3), NY-EM (pGL-SI_R3), and NY-EM2 were verified for the presence of plasmid by subsequent selections and restriction digestion analysis.
- CSD-SIase in the modified recombinant strain NY-EM2 (pGL-SI_R3) and control recombinant strain NY-EM (pGL-SI_R3) were grown in Synthetic Dropout Media without tryptophan.
- Cells were grown in SD Trp- medium with 2% glucose up to late logarithmic phase and induced by addition of 2% galactose for production of CSD-SIase.
- Example 7 Microscopy of immunofluorescence labelled yeast cells
- yeast strains NY-EM2 pGL-empty
- NY-EM2 pGL-SI_R3
- NY-YM2 pGH-empty
- NY-YM2 pGH-YM2
- the cells were washed with phosphate buffered saline (PBS) and treated with 3.7 % formaldehyde in PBS at room temperature for 15 min. After fixation, the cells were washed with PBS and attached to a polylysine coated slide. Fixed cells were coated with 5% bovine serum albumin (BSA) in PBS at room temperature for 20 minutes in order to avoid non-specific binding of antibodies. Coated cells were washed with PBS containing 1% BSA (PBS-B) and incubated with anti-sucrose isomerase primary antibody developed in rabbit in PBS-B for 30 min at room temperature.
- BSA bovine serum albumin
- Antibody bound cells were washed thrice in PBS-B and incubated with biotinylated anti-rabbit secondary antibody for another 30-60 minutes at room temperature. The cells were washed with PBS-B for thrice to remove the unbound antibodies and incubated with streptavidin (AlexaFluor488, Invitrogen) in PBS at room temperature for 30-60 minutes. The cells were washed and a drop of DAPI in an aqueous mounting medium was added for the staining the DNA of mounted cells and for fixing the cover-slip.
- Immunofluorescence analysis was performed using excitation which gives a Cyan-Green color at absorbance 495nm and excitation at 5l9nm wavelength for Alexa-488 staining and 345nm absorbance spectra and 455nm emission spectra for DAPI staining.
- Lane 1 and 2 depict control strain and strain expressing CSD-SIase constitutively, respectively.
- Lane 3 and 4 depict uninduced strain carrying inducible construct and induced strain for expression of CSD-SIase, respectively.
- Cell surface displayed GPI-fused Slase were detected in the I st row by using anti-Sucrose isomerase antibody produced in rabbit, biotinylated goat anti -rabbit IgG and Streptavidin Alexa Fluor® 488 which is a biotin-binding protein (streptavidin) covalently attached to a fluorescent label.
- DAPI stain was used to visualize the nucleus in the 2 nd row.
- the normal images of the cells were viewed by Nomarski differential interference contrast microscopy in the 4 th row.
- the images were taken with an inverted Nikon Eclipse 50i fluorescent microscope under 200x magnification using different filters.
- Overlay of both Alexa and DAPI staining in the 3 rd row shows the number of yeast cells stained with cell surface displayed recombinant sucrose isomerase.
- yeast strains NY-EM pGL-SI_R3
- NY-EM2 pGL-SI_R3
- NY-YM pGH-SI_R3
- NY-YM2 pGH-SI_R3
- Equal amount of cells were lysed in lysis buffer (50 mM Tris-HCl pH 8.0, 1% DMSO, 50-200 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 pg/ml leupeptin, 1 pg/ml pepstatin A) using acid washed glass beads.
- lysis buffer 50 mM Tris-HCl pH 8.0, 1% DMSO, 50-200 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 pg/ml leupeptin, 1 pg/ml pepstatin A
- the cell lysates were subject to SDS-PAGE and Western blot analysis.
- Anti-sucrose isomerase antibody developed in rabbit was used as primary antibody and goat anti rabbit AP-conjugate (alkaline phosphatase conjugate) was used as secondary antibody.
- the blots were developed using BCIP/NBT (5-bromo-4-chloro-3- indolylphosphate/nitro blue tetrazolium) substrate for the detection.
- CSD-SIase The activity of CSD-SIase was examined by incubating cells with 500mM sucrose solution in 20 mM citrate acetate buffer (pH 6.5) with I OmM CaCFas an additive and the reaction mixture was incubated at l2°C for 8 hrs. The enzymatic reaction was stopped by deactivating the enzyme at 95 °C in a boiling water bath for 10 min.
- Fig. 7 shows the expression profile of CSD-SIase by immunoblot analysis from different fractions of cell lysate from constitutive or inducible expression strains. Equal amount of cells were lysed and the whole cell lysate (lane 1 and 5), supernatant (lane 2 and 6) and pellet (lane 3 and 7) fractions were separated on SDS-PAGE and transferred to nitrocellulose membrane for Western blot analysis. Rabbit anti-SIase antibody and Goat anti-rabbit secondary antibody were used for detection. Lane 8 depicts protein molecular weight marker and Lane 9 depicts purified recombinant Slase.
- sucrose isomerase displayed on the yeast cell wall was confirmed by Western blot analysis (in lane 5 - 7), whereas there is no signal for sucrose isomerase in control strain (lane 1 - 3). Moreover, the cell membrane fraction (lane 7) showed that the majority of sucrose isomerase is present on the cell wall.
- Example 9 Fermentation kinetics and cell surface display for recombinant transformed strains exhibiting constitutive expression
- Fermentation of yeast strain NY-YM2 was carried out in defined media without uracil at 30°C for 42 hrs. Samples were collected at different time points and tested for growth and CSD-SIase activity.
- the enzyme assay was carried out in 20 mM citrate acetate buffer (pH 6.5) with 10 mM CaCk , 8.5% sucrose solution and 5 OD units of CSD-SIase cells (1 OD 6 OO is roughly 3x 10 7 cells/ml).
- the reaction mixture was incubated at l2°C for 4 hrs.
- the enzymatic reaction was stopped by deactivating the enzyme at 95°C in a boiling water bath for 10 min.
- the reaction mixtures were subject to HPLC analysis to confirm the residual substrate and product formation.
- Fig. 8 shows the fermentation kinetics and cell surface displayed Slase activity of recombinant strain producing CSD-SIase by constitutive expression strain NY-YM2 (pGH- SI_R3).
- the NY-YM2 (pGH-SI_R3) strain is constitutively producing modified sucrose isomerase (GPI-SIase), which is GPI anchor protein fused to sucrose isomerase.
- GPI-SIase modified sucrose isomerase
- the produced GPI-SIase is subsequently displayed on the cell surface of the NY- YM2 (pGH-SI_R3) strain which enabled it to convert sucrose in to trehalulose when cells were tested for sucrose isomerase activity throughout the fermentation.
- Example 10 Fermentation kinetics and cell surface display for recombinant transformed strains exhibiting inducible expression
- Fermentation of NY-EM2 (pGL-SI_R3) yeast strain was carried out in defined media without uracil at 30 °C for 42 hrs. Samples were collected at different time points and tested for growth and CSD-SIase activity. The enzyme assay was carried out in 100 mM citrate acetate (pH 6.5) with 150 mM NaCb , 8.5% sucrose solution and 5 OD units of CSD-SIase cells (1 OD 6 oo is roughly 3x 10 7 cells/ml). The reaction mixture was incubated at l4°C for 4 hrs. The enzymatic reaction was stopped by deactivating the enzyme at 95 °C in a boiling water bath for 10 min. The reaction mixtures were subject to HPLC analysis to confirm the residual substrate and product formation with appropriate standards.
- Fig. 9 shows the fermentation kinetics and cell surface displayed sucrose isomerase activity of recombinant strain producing CSD-SIase by inducible expression strain NY-EM2 (pGL-SI_R3).
- Fig. 10 shows the expression profile of CSD-SIase by immunoblot analysis from samples collected from constitutive [NY-YM2 (pGH-SI)] or inducible expression [NY-EM2 (pGL-SI)] strains at different fermentation time points. Equal amount of cells were collected at different fermentation time points and analyzed for the expression profile of CSD-SIase. The cells were lysed using glass beads in yeast cell lysis buffer and total cell lysate was separated on 10 % SDS- PAGE and were analyzed by Western blot. Rabbit anti-sucrose isomerase antibody and goat anti-rabbit secondary antibody was used for detection. The abbreviations used in the figure are C for purified Slase as positive control, M for protein molecular weight marker, kDa for Kilo Dalton and Ab for Antibody.
- sucrose isomerase is produced constitutively from the beginning in NY-YM2 (pGH-SI_R3), whereas in NY-EM2 (pGL-SI_R3) it is produced only after induction.
- Example 12 Production of whole cell biocatalysts with cell surface display
- the cells were grown in defined media comprised of base medium components (10 g/L (NH 4)2 S0 4 , 10 g/L KH 2 P04, 0.5 g/L CaCl 2 .2FbO, 0.5 g/L NaCb and 3 g/L MgSo 4. 7H 2 0), trace elements (278 mg/L FeS0 4. 7H 2 0, 288 mg/L ZnS0 4. 7H 2 0, 80 mg/L CuS0 4.
- base medium components (10 g/L (NH 4)2 S0 4 , 10 g/L KH 2 P04, 0.5 g/L CaCl 2 .2FbO, 0.5 g/L NaCb and 3 g/L MgSo 4. 7H 2 0
- trace elements (278 mg/L FeS0 4. 7H 2 0, 288 mg/L ZnS0 4. 7H 2 0, 80 mg/L CuS0 4.
- Example 13 Production of trehalulose using CSD-SIase cell
- CSD-SIase cells produced in previous example was used as whole cell biocatalyst.
- the optimization of process parameters for the production of trehalulose was carried out with varying pH and temperature, which were used for the production of trehalulose.
- trehalulose from sucrose was carried out by using 5-50 OD units more precisely, 10 OD units of CSD-SIase cells (1 OD 6 oo is roughly 3 x 10 7 cells/ml).
- the cells were contacted with varying concentration of sucrose, more particularly 10%, 20%, 30%, 40% and 45% sucrose solution, in 20 mM citrate acetate buffer (pH 6.5) with 10 mM CaCFas an additive atl2°C for 12-24 hrs.
- the sugar solution was subjected to cation and anion exchange resins to remove salt and ions present in buffer solutions. Furthermore, the sugar solution was concentrated using rotary vacuum evaporator system and subsequently passed through a column packed with activated charcoal, in order to remove the color. The purity of the product was analyzed by HPLC and ions contaminations were analyzed in ion chromatography.
- the enzyme assay was carried out using 1 OD, 3 OD and 5 OD units of CSD-SIase cells (1 OD 6 oo is roughly 3 x 10 7 cells/ml) in 20 mM citrate acetate buffer (pH 6.5) with 10 mM CaCF and 8.5% sucrose solution.
- the reaction mixture was incubated at l2°C for 8 hrs.
- the enzymatic reaction was stopped by deactivating the enzyme at 95°C in a boiling water bath for 10 min.
- the reaction mixtures were subjected to HPLC analysis to confirm the residual substrate and product formation with appropriate standards.
- Fig. 11 shows the product formation kinetics using different amount of CSD-SIase cells.
- the recombinant strain exhibiting constitutive expression was used.
- This result shows the product formation kinetics by different amount of CSD-SIase whole cell biocatalyst.
- the results show that the production of trehalulose increases proportionately related to the amount of CSD-SIase cells used in given reaction time with same amount of substrate.
- 5 OD cells were used, 11% to 45% product is formed between 0.5 to 24 hrs of reaction time, while only 6% to 19% product is formed in the same time when used 1 OD cells are used. Therefore, amount of whole cell biocatalyst can be increased up to 50 OD units for the bioconversion reaction for efficient conversion of sucrose in to trehalulose.
- Example 15 Product formation kinetics using different amounts of sucrose
- the cells were harvested and used for analysis of product formation kinetics by CSD-SIase cells.
- the enzyme assay was carried out in 20 mM sodium acetate (pH 6.5) with 10 mM CaCb as an additive with different concentration of substrate and 5 OD units of CSD-SIase (1 OD 6 oo is roughly 3 x 10 7 cells/ml).
- the recombinant strain exhibiting constitutive expression was used.
- the reaction mixture was incubated at l2°C for 8 hrs.
- the enzymatic reaction was stopped by deactivating the enzyme at 95°C in a boiling water bath for 10 min.
- the reaction mixtures were subjected to HPLC analysis to confirm the residual substrate and product formation with appropriate standards.
- Fig. 12 shows the product formation kinetics using different amount of sucrose as substrate with CSD-SIase.
- Example 16 Chromatogram of bioconversion of sucrose to trehalulose by recombinant strain exhibiting constitutive expression
- FIG. 13 depicts the results of HPLC analysis of bioconversion of sucrose into trehalulose by CSD-SIase strain.
- Figure A presents the chromatogram of blank substrate (sucrose). Chromatograms of bioconversion performed using NY-YM2 (pGH-SI_R3) and NY-YM (pGH-SI_R3) strains are shown as figure B and C, respectively.
- NY-YM pGH-SI_R3 strain constitutively producing CSD-SIase is able convert sucrose in to trehalulose but besides the formation of trehalulose the fructose and glucose were also formed due the invertase activity of the yeast strain S. cerevisiae.
- the NY-YM2 (pGH-SI_R3) strain show dramatic decrease in fructose and glucose level as the major sucrose invertase and symporter, SUC2 and AGT1 are deleted in this strain.
- the sucrose (substrate) was mainly converted to trehalulose by CSD-SIase.
- Example 17 Bioconversion kinetics of CSD-SIase produced by recombinant strain exhibiting constitutive expression
- CSD-SIase yeast cells [NY-YM2 (pGH-SI_R3)] were incubated with 8.2% sucrose in 10 mM calcium acetate (pH 6.5) with 150 mM NaCFand incubated at l2°C for different time points. The enzymatic reaction was stopped by deactivating the enzyme at 95°C in a boiling water bath for 10 min. The reaction mixtures were subject to HPLC analysis to confirm the residual substrate and product formation with appropriate standards.
- Fig. 14 depicts the bioconversion kinetics of CSD-SIase produced by constitutive expression strain [NY -YM2 (pGH-SI)] .
- Example 18 Bioconversion kinetics of CSD-SIase produced by recombinant strain exhibiting inducible expression
- CSD-SIase yeast cells [NY-EM2 (pGL-SI_R3)] were incubated with 8.2% sucrose in 10 mM calcium acetate (pH 6.5) with 150 mM NaCFand incubated at l2°C for different time points. The enzymatic reaction was stopped by deactivating the enzyme at 95°C in a boiling water bath for 10 min. The reaction mixtures were subject to HPLC analysis to confirm the residual substrate and product formation with appropriate standards.
- Fig. 15 shows the bioconversion kinetics of CSD-SIase produced by inducible expression strain [NY-EM2 (pGL- SI_R3)].
- Example 19 Temperature optima profile of CSD-SIase and native enzyme
- Temperature optimum was determined by incubating the reaction mixture with constitutive produced CSD-SIaseand the respective native Slase at various temperatures ranging from l0°C - 70°C in 10 mM calcium acetate (pH 6.5) with 150 mM NaCEand incubated for 12 hrs. Enzyme activities were determined at pH 6.5 and the relative activity was calculated by assuming that the activity observed at 30°C for CSD-SIase and 40°C for native Slase was 100%.
- Fig. 16 shows the temperature optima profiles of CSD-SIase and native Slase.
- Example 20 pH profile of CSD-SIase and native enzyme
- the pH optimum was determined by incubating the constitutively produced CSD-SIase and native Slase with sucrose in assay buffer with different pH and 10 mM CaCb as an additive. Enzyme activities were measured at l2°C and the relative activity was calculated by assuming that the activity observed at pH 6.5 was 100%.
- Fig. 17 shows the pH profiles of CSD-SIase and native Slase.
- CSD-SIase The stability of CSD-SIase were checked by incubating the CSD-SIase cells in sucrose isomerase buffer at optimum temperature and cells were collected at different time points for residual CSD-SIase activity analysis.
- the enzyme assay was carried out in 10 mM calcium acetate (pH 6.5) with 150 mM NaCh and 8.5% sucrose solution and 5 OD units of CSD-SIase cells (1 OD 6OO is roughly 3 x 10 7 cells/ml).
- Fig. 18 shows the residual activity of CSD-SIase enzymes compared to native Slase enzyme. This result shows that the CSD-SIase cells or whole cell biocatalyst retains 80%, 70%, 55% and 50% of its activity after 24 hrs, 48 hrs, 96 hrs and 120 hrs respectively in optimum reaction condition, which is slightly lower than the native free sucrose isomerase activity.
- the stability of native sucrose isomerase falls rapidly after 72 hrs whereas the CSD-SIase activity retains stability for a longer period. Therefore, the CSD-SIase has almost similar stability to the native enzyme for continuous bioconversion.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides for a novel whole cell biocatalyst for the production of trehalulose. The invention represents an advancement in the field of enzyme engineering and discloses a novel double deletion mutant whose invertase and permease encoding genes have been made inoperative. Further, the mutant host cell comprises an expression construct encoding sucrose isomerase enzyme fused to a cell surface anchor protein. The recombinant cell can be used as a biocatalyst for effective conversion of sucrose to trehalulose.
Description
NOVEL WHOLE-CELL BIOCATALYST FOR THE PRODUCTION OF
TREHALULOSE
FIELD OF INVENTION
The present invention pertains to the field of enzyme engineering. More particularly, the invention relates to a novel whole cell biocatalyst for production of trehalulose from sucrose and the process for development thereof.
BACKGROUND OF THE INVENTION
Trehalulose (a-D-glucosylpyranosyl-l,l-D fmctofuranose) is a structural isomer of sucrose which is composed of glucose and fructose joined by an alpha (1-1) glycosidic bond. It is naturally present in honey in very low quantities. In addition to sweetness, trehalulose shows physical and organoleptic characteristics that are very similar to sucrose. Further, trehalulose is non-cariogenic, has low glycemic index and is a low-insulinemic sugar. Absence of toxicity, mutagenicity and other side effects makes trehalulose a suitable substitute for sugar in various foods and beverages. Trehalulose has been reported to be suitable for consumption by public.
The overconsumption of sugar is potentially linked to many diseases which creates a growing need for sugar substitutes. Trehalulose, being one of the most potent sugar substitute has a huge demand in the healthy lifestyle segment wherein the consumers demand a suitable alternative to sucrose for following a low glycemic diet and avoidance of significant blood sugar variation.
Enzymatic bioconversion is a preferred method for the production of trehalulose because of the complexity in its chemical synthesis.
The current methods used for conversion of sucrose into isomers, particularly trehalulose by using sucrose isomerase activity involves following approaches:
1. usage of non- viable organism which converts sucrose in to trehalulose
2. production of sucrose isomerase in recombinant host
3. isolation and purification of native or recombinant sucrose isomerase
4. immobilization of sucrose isomerase for bioconversion
But, the various approaches which have been used till date suffers from some limitations and drawbacks such as low expression level of sucrose isomerase, additional cost in isolating the enzyme produced, difficulties in identifying appropriate immobilization method for retaining the activity of the enzyme, instability of the enzyme, recycling of the enzymes and the bioconversion
activity is restricted to a narrow range of pH and temperature. Further, the bioconversion activity is limited to a narrow range of pH and temperature.
For the first time, the inventors have identified the above issues and addressed the same by employing a multidimensional approach wherein recombinant yeast strains have been created by inactivating sucrose hydrolyzing genes in a host cell combined with the expression of sucrose isomerase on the surface of the host by way of fusion protein. In the absence of SUC2 and AGT1 gene, the host organism is unable to utilize the disaccharide sucrose for metabolism. Subsequently, the yield of trehalulose is high and the downstream processing cost is low.
Thus, the present invention thus addressed the drawbacks of existing approaches to solve a long-standing problem of providing an efficient, cheap and industrially-scalable means for production of trehalulose.
SUMMARY OF THE INVENTION
The present invention relates to a novel whole cell biocatalyst for production of trehalulose from sucrose. The recombinant biocatalyst has been developed by deletion of SUC2 and AGT1 encoding genes, which are responsible for hydrolyzing sucrose in a host cell combined with the expression of sucrose isomerase on the surface of the host by way of fusion protein. The biocatalyst shows dramatic decrease in utilization of the disaccharide sucrose for metabolism. The sucrose remained available for the bioconversion in to trehalulose and the recombinant cells exhibits a high rate of bioconversion.
Further, the invention discloses a modified open reading frame encoding for sucrose isomerase enzyme fused to the C-terminus of GPI anchor protein. The invention also discloses vectors comprising the modified open reading frame under the control of constitutive or inducible promoter.
Further, the invention provides for a fusion protein which is a sucrose isomerase enzyme fused to C-terminus of a cell surface anchor protein.
The invention also provides for an efficient bioconversion process for production of trehalulose using the recombinant biocatalyst. The one-step production process can be performed under a wide range of physical and chemical conditions to obtain optimum yield of trehalulose. Further, the biocatalyst used in the process is reusable and provides for efficient and cheap downstream processing.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the vector map of recombinant plasmid pGH-SI_R3 which shows the gene construction for constitutive expression of recombinant fusion protein.
Fig. 2 shows the vector map of recombinant plasmid pGL-SI_R3 which shows the gene construction for inducible expression of recombinant fusion protein.
Fig. 3 shows the sucrose and residual sugars after growth of wild type strains (shown as wild type) and modified strains (shown as NY -EM2 and NY -YM2) in the presence of synthetic growth media containing sucrose, glucose and fructose.
Fig. 4 shows the residual sucrose after growth of wild type strains compared with NY- EM2 and NY-YM2 strains in synthetic growth media containing 20 g/L sucrose, 20 g/L sucrose supplemented with 20 g/L glucose or 20 g/L sucrose supplemented with 20 g/L fructose.
Lig. 5 shows the residual invertase activity of NY -EM2 and NY -YM2 strains compared to respective wild type strains.
Lig. 6 shows the microscopy of immunofluorescence-labeled recombinant yeast cells.
Lig. 7 shows the expression profile of cell surface displayed sucrose isomerase by immunoblot analysis from different fractions of cell lysate from constitutive and inducible expression strains compared with the native strains.
Lig. 8 shows the fermentation kinetics and cell surface displayed sucrose isomerase activity by recombinant constitutive expression strain NY-YM2 (pGH-SI_R3).
Lig. 9 shows the fermentation kinetics and cell surface displayed sucrose isomerase activity by recombinant inducible expression strain NY-EM2 (pGL-SI_R3).
Lig. 10 shows the expression profile of CSD-SIase by immunoblot analysis from samples collected from constitutive [NY-YM2 (pGH-SI)] and inducible expression [NY-EM2 (pGL-SI)] strains at different fermentation time points.
Lig. 11 shows the product formation kinetics using different amount of CSD-SIase cells.
Lig. 12 shows the product formation kinetics using different amount of sucrose as substrate with CSD-SIase.
Lig. 13 shows the chromatogram of samples after bioconversion of sucrose into trehalulose by recombinant strains constitutively producing CSD-SIase.
Lig. 14 shows the bioconversion kinetics of CSD-SIase produced by constitutive expression strain [NY-YM2 (pGH-SI)].
Fig. 15 shows the bioconversion kinetics of CSD-SIase produced by inducible expression strain [NY-EM2 (pGL-SI)].
Fig. 16 shows the temperature optima profiles of CSD-SIase and native Slase.
Fig. 17 shows the pH profiles of CSD-SIase and native Slase.
Fig. 18 shows the residual activity of CSD-SIase enzymes compared to native Slase enzyme.
DETAILED DESCRIPTION OF THE INVENTION
The present invention discloses a genetically modified host cell, which can be used as a whole cell biocatalyst for the production of trehalulose from sucrose.
The invention contemplates a multidimensional approach for achieving a high rate of bioconversion of sucrose into trehalulose using a whole cell biocatalyst. The biocatalyst created for efficient, cheap and industrially scalable bioconversion of sucrose to trehalulose is characterized by the following:
i. Deletion of the genes involved in sucrose hvdrolvzation - Sucrose is utilized by a large array of host organisms for metabolism. Therefore, most of the sucrose present in the substrate is utilized by the host organism and is not available for bioconversion. The present invention overcomes this issue.
ii. Transformation of the host cell for expression of sucrose isomerase on the surface of the host cells - By this approach, the substrate to be processed has free access to the enzyme and does not need to cross a membrane barrier. Further, yield increases and downstream processing cost decreases as a result.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the methods belong. Although any methods and compositions similar or equivalent to those described herein can also be used in the practice or testing of the methods and compositions, representative illustrative methods and compositions are now described.
Where a range of values is provided, it is understood that each intervening value between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within by the methods and compositions. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within by the methods and compositions, subject to any specifically excluded limit
in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the methods and compositions.
It is appreciated that certain features of the methods, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the methods and compositions, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. It is noted that, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element.
As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other embodiments without departing from the scope or spirit of the present methods. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.
The term“host cell” includes an individual cell or cell culture which can be, or has been, a recipient for the subject of expression constructs. Host cells include progeny of a single host cell. Host cell can be any expression host including prokaryotic cell such as but not limited to Escherichia coli, Bacillus subtilis, Pseudomonas putida, Corynebacterium glutamicum or eukaryotic system, such as, but not limited to Saccharomyces cerevisiae, Pichia pastoris, Hansenula polymorpha.
The term“recombinant strain” refers to a host cell which has been transfected or transformed with the expression constructs or vectors of this invention.
The term“expression cassette” denotes a gene sequence used for cloning in expression vectors or in to integration vectors or integrated in to coding or noncoding regions of chromosome of the host cell in a single or multiple copy numbers, where the expression cassette directs the host cell's machinery to make RNA and protein encoded by the expression cassette.
The term“expression construct” is used here to refer to a functional unit that is built in a vector for the purpose of expressing recombinant proteins/peptides, when introduced into an appropriate host cell, can be transcribed and translated into a fusion protein which is displayed on the cell wall.
The term“promoter” refers a DNA sequences that define where transcription of a gene begins. Promoter sequences are typically located directly upstream or at the 5' end of the transcription initiation site. RNA polymerase and the necessary transcription factors bind to the promoter sequence and initiate transcription.
The term“constitutive promoter” is more commonly defined the promoter which allows continual transcription of its associated genes as their expression is normally not conditioned by environmental and developmental factors. Constitutive promoters are very useful tool in genetic engineering because constitutive promoters drive gene expression under inducer-free conditions and often show better characteristics than commonly used inducible promoters.
The term“inducible promoter” refers the promoters that are induced by the presence or absence of biotic or abiotic and chemical or physical factors. Inducible promoters are a very powerful tool in genetic engineering because the expression of genes operably linked to them can be turned on or off at certain stages of development or growth of an organism or in a particular tissue or cells.
The term“transcription” refers the process of making an RNA copy of a gene sequence. This copy, called a messenger RNA (mRNA) molecule, leaves the cell nucleus and enters the cytoplasm, where it directs the synthesis of the protein, which it encodes.
The term“translation” refers the process of translating the sequence of a messenger RNA (mRNA) molecule to a sequence of amino acids during protein synthesis. The genetic code describes the relationship between the sequence of base pairs in a gene and the corresponding amino acid sequence that it encodes. In the cell cytoplasm, the ribosome reads the sequence of the mRNA in groups of three bases to assemble the protein.
The term“terminator sequence” refers to a nucleotide sequence that is required for the termination reaction of the transcription process. Termination involves recognition of the point at which no further bases should be added to a growing RNA chain.
The term "fusion protein" refers to a polypeptide which comprises protein domains from at least two different proteins. As used herein, the fusion protein is sucrose isomerase fused to C- terminus of a cell surface anchor protein.
The term“sucrose hydrolyzing genes” refers to genes which are responsible for sucrose hydrolysis. As used herein, the term sucrose hydrolyzing genes refers to SUC2 invertase and AGT1 alpha-glucoside transporter.
The term“inducible excision system” refers to site-specific recombinase technologies which can be used for efficiently regulating the excision or deletion of genes. As used herein, the inducible excision system employed in the invention is cre-lox excision system.
The term“replication origin” as used herein refers to the site on a nucleic acid sequence at which replication is initiated. Bacterial or yeast replication origins may be required in a recombinant vector for significant expression of the desired polypeptide.
The term“selection marker gene” refers to a gene determinant that, when expressed in the cell, confers a specific set of characteristics upon the cell that allows such a cell to be distinguished, or selected out, from other cells not carrying or expressing said gene determinant.
The term "anchor protein" or "cell surface anchor protein" is used to describe proteins or peptides which are anchored to the external surface of the plasma membrane generally by covalent bonding to glycans containing phosphatidyl inositol. The structures to which the anchor protein or peptide is bonded are often referred to as glycosylphosphatidylinositol or GPIs. In all cells, anchor proteins covalently bonded to GPIs are found on the external face of the plasma membrane of cells or on the lumenal surface of secretory vesicles. As used herein, the anchor protein is a GPI anchor protein, AGA2 which is fused in frame to the N-terminus of sucrose isomerase.
The term“modified sucrose isomerase” is used to refer to a fusion protein containing GPI anchor protein such as AGA2 fused in frame to the N-terminus of sucrose isomerase. The N- terminus region of the fusion protein will anchor to the cell surface of the host cell and display the free sucrose isomerase over the cell wall for bioconversion of sucrose into trehalulose.
The term“specific activity” is defined as the micromoles of product formed per minute per milligram of enzyme.
“NY-YM” denotes the wild type yeast strain ATCC 208352 and“NY-YM2” denotes the modified yeast strain after deletion of invertase (SUC2) and symporter (AGT1) genes. NY-YM2 is used for transformation of construct pGH-SI_R3 under constitutive promoter.
“NY-EM” strain denotes the wild type yeast strain ATCC 208289 and“NY-EM2” denotes the modified yeast strain after deletion of invertase (SUC2) and symporter (AGT1) genes. NY-EM2 is used for transformation of construct pGL-SI_R3 under inducible promoter.
“GPI-SI” nucleotide sequence designates fusion protein of sucrose isomerase fused in frame with cell surface anchor protein.
“NY-YM2 (pGH-SI_R3)” designates the final transformed yeast strain having the artificially synthesized gene encoding for sucrose isomerase of Pseudomonas mesoacidophila under constitutive promoter control.
“NY-EM2 (pGL-SI_R3)” designates the final transformed yeast strain having the artificially synthesized gene encoding for sucrose isomerase of Pseudomonas mesoacidophila under inducible promoter control.
Before the modified expression cassette, vectors, recombinant hosts, peptides and methods for production of trehalulose are described in greater detail, it is to be understood that the invention is not limited to particular embodiments and may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the methods and compositions will be limited only by the appended claims.
The present invention discloses novel whole cell biocatalysts for production of trehalulose from sucrose and the process for development thereof. Further, the invention also nucleic acids which encode sucrose isomerase enzyme fused to a cell surface anchor protein. Further, the invention discloses a recombinant cell in which the invertase and sucrose permease encoding genes have been made inoperative, and the recombinant cell has been engineered to display sucrose isomerase enzyme on the cell surface.
In one aspect, the present invention provides a modified nucleic acid encoding sucrose isomerase gene fused in frame with cell surface anchor proteins. The modified nucleic acid may employ native genes or synthetic genes optimized as per the codon preference of the host organism.
In one embodiment, the modified nucleic acid is the nucleic acid encoding for sucrose isomerase (Slase) of Pseudomonas mesoacidophila, fused in frame with cell surface anchor proteins, such as, but not limited to GPI proteins like AGA2 protein.
In a preferred embodiment, the modified nucleic acid is represented by SEQ ID NO: 1.
In another aspect, the invention provides for a fusion protein, which was constructed by the cell surface anchor protein of Saccharomyces cerevisiae being fused in-frame with the N- terminus of sucrose isomerase (Slase) of Pseudomonas mesoacidophila MX-45. In a preferred embodiment, the fusion protein is represented by SEQ ID NO:6.
In another aspect, the present invention provides a modified expression cassette comprising a promoter, a modified open reading frame encoding for sucrose isomerase enzyme fused to the C-terminus of GPI anchor protein and a terminator sequence. The promoter chosen may either be for constitutive expression or for inducible expression. The modified expression cassette can express sucrose isomerase on the surface of a wide range of host organisms, such as, but not limited to Saccharomyces cerevisiae.
In one embodiment, the construct carries a constitutive promoter, such as, but not limited to, GAPDH promoter.
In yet another embodiment, the construct carries an inducible/regulated promoter, such as, but not limited to GAL1, pGALlO, pSUC2, pXYL or pADH promoter.
In a preferred embodiment, the expression cassette for constitutive expression comprises the modified nucleic acid represented by SEQ ID NO: l, a GAPDH promoter represented by SEQ ID NO:2 and a GAPDH terminator represented by SEQ ID NO:4.
In another preferred embodiment, the expression cassette for inducible expression comprises the modified nucleic acid represented by SEQ ID NO: l, a GAL1 promoter represented by SEQ ID NOG and a MFa terminator represented by SEQ ID NO: 5.
In another aspect, the invention provides for expression vectors comprising the expression cassette. The modified expression cassettes are cloned into expression vectors for recombinant expression. The expression vectors can be used in both prokaryotic as well as eukaryotic organisms. Hence, the shuttle vector used provides for a number of selectable markers such as, but not limited to, ampicillin resistance marker, uracil selectable marker or tryptophan selectable maker. The vector also comprises of bacterial origin of replication, 2m for replication in yeast or CEN for replication in yeast.
In one embodiment, the expression vector for constitutive expression is a pYEP plasmid, more specifically a pGH plasmid. The recombinant plasmid contains the open reading frame, a constitutive GAPDH promoter, GAPDH terminator, ampicillin resistance marker for bacterial selection, pBR322 for bacterial origin of replication, URA (uracil) auxotrophic markers for selection in yeast and 2m for replication in yeast.
In a preferred embodiment, the modified sequence encoding for the fusion protein was cloned in to pGH yeast expression vector using Nhel and Xhol sites in frame with GPI anchor which is under control of constitutive promoter yielding pGH_GPI-SI_R3 (also referred to as
pGH-SI_R3). GPI-sucrose isomerase (GPI-SI) gene in pGH-SI_R3 plasmid is flanked by EcoRI at 5’end and Hindlll at 3’end. Sall and Xhol were lost during the cloning procedure. The modified vector is depicted in Figure 1.
In another embodiment, the expression vector for inducible expression is a pRS3 l4 plasmid, more specifically, pGL plasmid. The recombinant plasmid contains an inducible promoter, MFa (Alpha-factor) terminator, Ampicillin resistance marker for bacterial selection, fl for bacterial origin of replication, TRP (tryptophan) auxotrophic markers for selection in yeast and CEN for replication in yeast.
In a preferred embodiment, the modified sequence was cloned in to pGL yeast expression vector using Nhel and Bam HI sites in frame with GPI anchor which is under control of inducible promoter yielding pGL_GPI-SI_R3 (also referred to as pGL-SI_R3). GPI-sucrose isomerase (GPI-SI) gene in pGL-SI_R3 plasmid is flanked by EcoRI at 5’end, and BamHI at 3’end. The modified vector is depicted in Figure 2.
In another aspect, the invention provides host cells in which sucrose hydrolyzing genes have been inactivated by knock-out or deletion.
In one embodiment, the invention provides yeast strains which lacks expression of both SUC2 invertase and AGT1 alpha-glucoside transporter. The strains are characterized by extremely low sucrose hydrolysis ability. Therefore, the problem of rapid depletion of sucrose due to metabolism of cells is avoided and the complete substrate is available for bioconversion to desirable products by cell surface display of recombinant enzymes.
In a preferred embodiment, the deletion of genes encoding for SUC2 and AGT1 in the host strain is done using an inducible gene excision system, such as, cre-lox system. Gene disruption cassettes designed with the heterologous dominant kanamycin resistant marker with a Cre/loxP mediated marker removal procedure is used. The loxP-Marker gene-loxP gene disruption cassettes are generated by PCR amplification using pUG6 vector as template. Flanking homology sequences to the AGT1 gene upstream and downstream to the target gene are added to the disruption cassette primers. The PCR product was used as a template for further long flanking homology ends using a 2nd set of primers to add more nucleotide sequence for an accurate homologous recombination.
In the preferred embodiment, the amplified products were used as deletion cassettes and transformed into yeast strain, such as, but not limited to, W303-1A or BJ5465 strains.
In another aspect, the invention provides for engineered strain which can grow in media with glucose or fructose. But the engineered strains show severe growth defect when grown in media with sucrose alone.
In one embodiment, it has been exhibited that the sucrose hydrolysis is dramatically decreased in engineered strains compared to their wild type strains. Additionally, the engineered strains NY-EM2 and NY-YM2 hydrolyzes sucrose very slowly in the presence of additional glucose or fructose in growth media when compared to its wild type strains.
In another embodiment, it is exhibited that the residual invertase activity of the engineered strains are reduced when compared to their wild type strains as depicted by sucrose isomerase assay conditions.
In yet another aspect, the invention provides for the development of recombinant host cells. In an embodiment, the recombinant plasmids encoding a cell surface anchor protein of Saccharomyces cerevisiae being fused in-frame with the N-terminus of sucrose isomerase (Slase) of Pseudomonas mesoacidophila, are transformed into a yeast host strains which lacks both SUC2 invertase and AGT1 alpha-glucoside transporter to create a whole cell biocatalyst with a high rate of bioconversion. The biocatalyst shows dramatic decrease in utilization of the disaccharide sucrose for metabolism. The sucrose remained available for the bioconversion in to trehalulose and the recombinant cells exhibits a high rate of bioconversion.
In yet another aspect, the engineered strain may also contain additional modifications for preproduction of AGA1 protein under control of GAL1 promoter and/or deletion of major Pir (Pir 1-3) proteins for enhanced display of cell surface anchor proteins.
In one embodiment, the invention relates to recombinant host cell which has been developed by deletion of SUC2 and AGT1 encoding genes in a host cell combined with the expression of sucrose isomerase on the surface of the host by way of fusion protein. The recombinant host cell has been engineered for constitutive expression.
In a preferred embodiment, the cells were treated to prepare electrocompetent cells. The recombinant plasmids pGH-SI_R3 were transformed in to electrocompetent cells by standard electroporation method. The strains transformed with pGH-SI_R3 were selected on SD-Ura plates.
In another embodiment, the invention relates to recombinant host cell which has been developed by deletion of SUC2 and AGT1 encoding genes in a host cell combined with the
expression of sucrose isomerase on the surface of the host by way of fusion protein. The recombinant host cell has been engineered for inducible expression.
In a preferred embodiment, the cells were treated to prepare electrocompetent cells. The recombinant plasmids pGL-SI_R3 were transformed in to electrocompetent cells by standard electroporation method. The strains transformed with pGH-SI_R3 were selected on SD-Trp plates.
In the preferred embodiments, the yeast strains used were procured from ATCC (American Type Culture Collection: Global Bioresource Centre) headquartered in Manassas, Virginia, USA. ATCC 208352 (Strain Designation: W303-la) has been used to develop MTCC 5985 recombinant host cell for constitutive CSD-SIase expression and ATCC 208289 (Strain designation: BJ5465) has been used to develop MTCC 5987 recombinant host cell for inducible CSD-SIase expression. Both the strains were deposited on 2lst January, 2015.
In another aspect of the invention, CSD-SIase shows significant bioconversion activity not only at the optimum temperature but even at lower temperatures in the range of l5-40°C as compared to the native enzyme.
In one embodiment, the invention provides that the optimum temperature for CSD sucrose isomerase is in the range of l5°C to 40°C, more precisely 25°C compared to native enzyme which is in the range of l5°C to 40°C, more precisely 30°C.
A further aspect of the present invention is that the optimum pH for CSD sucrose isomerase is in the range of 4 to 6.5, more precisely 6.2 as compared to native enzyme which is in the range of 5.0 to 6.7, more precisely 6.5. Thus, the cell surface displayed sucrose isomerase exhibits broader pH tolerance higher than that of the native enzyme.
In another aspect, the invention provides for an industrially scalable process for production of trehalulose.
In one embodiment, the process includes culturing the recombinant Saccharomyces cerevisiae host cells in defined media. The culture medium has pH ranging between 4 to 6.5 and temperature maintained between l5°C to 30°C. Further, the recombinant host cells are contacted with 10% to 45% sucrose solution and trehalulose is harvested from the solution.
Yet another aspect of the invention provides that when cells are contacted with sucrose solution for the formation of trehalulose, the bioconversion increases depending on the amount of cell used.
In one embodiment, it is exhibited that when 5 OD units of stationary phase cell surface displayed-sucrose isomerase cells (1 OD = 3xl07 cells/ml) were used, upto 40% product is formed between 1 to 6 hrs of reaction time.
In another aspect of the invention, it is exhibited that the bioconversion depends upon the amount of substrate used.
In one embodiment, it is exhibited that the amount of substrate can be increased upto 45% for efficient conversion of sucrose into trehalulose.
Another aspect of the invention provides that cell surface displayed sucrose isomerase is stable and retains more than 50% of its activity for up to 120 hrs at optimum pH and temperature when compared to native enzyme.
EXAMPLES
The following examples particularly describe the manner in which the invention is to be performed. But the embodiments disclosed herein do not limit the scope of the invention in any manner.
Example 1: Gene construction for constitutive expression of recombinant fusion protein GPI-SI in Saccharomyces cerevisiae
Gene encoding for sucrose isomerase(SIase) was modified for expression of sucrose isomerase on the surface of Saccharomyces cerevisiae cells. The modified gene contains a constitutive promoter, a modified open reading frame encoding for sucrose isomerase enzyme fused to the C-terminus of GPI anchor protein and a terminator sequence.
The sequence of the modified open reading frame encoding for sucrose isomerase enzyme fused to the C-terminus of GPI anchor protein is represented by SEQ ID NO: 1.
The constitutive promoter used is GAPDH promoter sequence which is represented by SEQ ID NO: 2. The terminator used is a GAPDH terminator which is represented by SEQ ID NO: 4.
This modified open reading frame has been artificially synthesized by using the sequence for sucrose isomerase of Pseudomonas mesoacidophilaMX-4-5 and the sequence of AGA2 protein from Saccharomyces cerevisiae.
The plasmid used in the process was a pYEP plasmid, more specifically pGH plasmid. The recombinant plasmid contains the open reading frame, a constitutive GAPDH promoter, GAPDH terminator, Ampicillin resistance marker for bacterial selection, pBR322 for bacterial
origin of replication, UR A (uracil) auxotrophic markers for selection in yeast and 2m for replication in yeast.
The modified sequence encoding for the fusion protein was cloned in to pGH yeast expression vector using Nhel and Xhol sites in frame with GPI anchor which is under control of constitutive promoter yielding pGH_GPI-SI_R3(also referred to as pGH-SI_R3). The vector map is represented in Figure 1. GPI-sucrose isomerase (GPI-SI) gene in pGH-SI_R3 plasmid is flanked by EcoRI at 5’end and Hindlll at 3’end. Sall and Xhol were lost during the cloning procedure. Recombinant plasmids were confirmed by restriction digestion analysis and followed by DNA sequencing.
Example 2: Gene construction for inducible expression of recombinant fusion protein GPI- SI in Saccharomyces cerevisiae
Gene encoding for sucrose isomerase (Slase) was modified for expression of sucrose isomerase on the surface of Saccharomyces cerevisiae cells. The modified gene contains an inducible promoter, a modified open reading frame encoding for sucrose isomerase fused to the C-terminus of GPI anchor protein and a terminator sequence.
The sequence of the modified open reading frame encoding for sucrose isomerase enzyme fused to the C-terminus of GPI anchor protein is represented by SEQ ID NO: 1.
The inducible promoter used is GAL1 promoter sequence which is represented by SEQ ID NO: 3. The terminator used is a MFa (Alpha-factor) terminator which is represented by SEQ ID NO: 5.
The plasmid used in the process was a pRS3l4 plasmid, more specifically pGL plasmid. The recombinant plasmid contains an inducible promoter, MFa (Alpha-factor) terminator, Ampicillin resistance marker for bacterial selection, fl for bacterial origin of replication, TRP (tryptophan) auxotrophic markers for selection in yeast and CEN for replication in yeast.
The modified sequence was cloned in to pGL yeast expression vector using Nhel and Bam HI sites in frame with GPI anchor which is under control of inducible promoter yielding pGL_GPI-SI_R3 (also referred to as pGL-SI_R3). The vector map is represented in Figure 2. GPI-sucrose isomerase (GPI-SI) gene in pGL-SI_R3 plasmid is flanked by EcoRI at 5’end, and BamHI at 3’end. Recombinant plasmids were confirmed by restriction digestion analysis and followed by DNA sequencing.
Example 3: Polynucleotide sequence for expression of sucrose isomerase and corresponding polypeptide sequence
A modified open reading frame represented by SEQ ID NO: 1 was artificially synthesized for encoding a fusion protein wherein a polynucleotide sequence coding for cell surface anchor protein was fused in-frame with a polynucleotide sequence encoding sucrose isomerase (Slase) enzyme.
The fusion protein obtained by translating the gene encoding for sucrose isomerase fused to the C-terminus of GPI anchor protein is represented by SEQ ID NO:6. The fusion protein is a cell surface anchor protein of Saccharomyces cerevisiae being fused in-frame with the N- terminus of sucrose isomerase (Slase) of Pseudomonas mesoacidophilaMX-4-5.
Example 4: Development of strain for reduced ability to hydrolyze sucrose by deletion of AGT1 and SUC2 gene
The yeast cells were grown in rich media such as Yeast Extract Peptone Dextrose (YEPD) broth and 50 mL of the yeast cells at log-phase were collected by centrifugation at 2000 g, washed with phosphate buffer twice and resuspended in 1M chilled sorbitol. The cells were washed once in 1M chilled sorbitol, resuspended in 5 mL of chilled sorbitol and used for the electro-transformation with the disruption cassettes for AGT1.
For deletion of AGT1 in the chromosome of S. cerevisiae, the gene disruption cassette was designed with the heterologous dominant KanR resistant marker with a Cre/loxP mediated marker removal procedure. The loxP-Marker gene-loxP gene disruption cassettes were generated by PCR amplification using pUG6 deletion cassette plasmid as template and primers having flanking homology sequences to the AGT1 gene (30 bp) upstream and downstream to the target gene followed by the sequence homologous to universal loxP-marker amplification sequence.
The disruption cassette used for deletion of AGT1 gene is represented by SEQ ID NO: 7.
The amplified PCR product was purified and was reused as template for second PCR amplification and primers having long flanking homology sequences to the AGT1 gene further upstream and downstream to the target gene followed by the sequence homologous to first set of deletion cassette amplification primer sequence.
The amplified loxP-marker gene-loxP gene disruption cassette with long (60 bp) flanking ends homology to AGT1 gene sequence was purified and were transformed into
electrocompetent yeast cells by electroporation using the rapid DNA transformation protocol as described in Methods in Enzymology, Vol 191.
The transformants were plated on YPD plates containing 200pg/mL G418 and incubated for 4 days at 28°C. Putative transformants obtained were restreaked on YPD agar plated containing 200 pg/mL G418. The transformants were verified by PCR with appropriate primers for confirmation of deletion of the AGT1 gene in the chromosome by comparing the amplified product with the PCR product obtained from the wild type genomic DNA. Among transformants, the strains NY-EM1 and NY-YM1 showed promising results with sucrose uptake studies which is used as host strain for further development.
SUC2 knockout cassette was designed using loxP flanking end with BLE (phleomycin) marker which confers resistance to phleomycin in yeast for the selection. The disruption cassette was PCR amplified using pUG66 deletion cassette plasmid as template and further amplified using the primary PCR product as template for long flanking homology ends with SUC2 upstream and downstream sequences in the primers.
The disruption cassette used for deletion of SUC2 gene is represented by SEQ ID NO: 8.
The PCR product was purified and transformed into electrocompetent NY-EM1 and NY- YM1 yeast cells and selected on YEPD plates containing 7.5 pg/mL phleomycin. The transformants were verified by PCR with respective primers for confirmation of deletion of the SUC2 gene in the chromosome and by comparing the amplified product with the PCR product obtained from the wild type genomic DNA.
The developed double deletion strain was designated as NY -EM2 and NY -YM2.
Example 5: Sucrose utilization studies by recombinant NY-EM2 and NY-YM2 strains
Among developed recombinant strains NY -EM2 and NY -YM2 showed promising results with sucrose uptake studies compared to their wild type and/or single mutant strains.
The double mutant strains NY -EM2 and NY -YM2 were tested for their ability to grow in media containing sucrose alone or in combination with glucose or fructose. The growth profile and the residual sugars present in growth media at different time points were analyzed for utilization of sugars for cell growth and the presence of residual invertase activity for sucrose hydrolysis respectively. The mutant strains showed slow growth behavior when grown in sucrose compared to their wild type background due to reduced ability of sucrose uptake and hydrolysis.
In the first instance, the uptake and utilization of sucrose, glucose and fructose were individually studied. In the presence of synthetic growth media containing of 37 g/L sucrose, the wild type strains and modified strains were grown. Samples were collected at different time points and the availability of residual sucrose, glucose and fructose were analyzed by HPLC analysis with appropriate standards.
Both NY -YM2 and NY -EM2 strains show dramatic reduction in sucrose hydrolysis when grown on synthetic growth media containing sucrose as carbon source compared to their wild type strains NY-YM and NY-EM, respectively. The NY-YM2 strain hydrolyzed only 22% of sucrose. Hence 78% of sucrose remains in the medium after 24hrs incubation whereas the wild type NY-YM hydrolyzed 52% of sucrose. Hence, only 48% of sucrose remains in the medium after 24hrs incubation. This result highlights that the NY-YM2 strain dramatically lost the ability to hydrolyze the sucrose for its growth and the use of this stain makes 30% more sucrose available for bioconversion in to trehalulose by the whole cell biocatalyst.
Similarly, the NY-EM2 strain hydrolyzed only 33% of sucrose. Hence, 67% of sucrose remains in the medium after 24hrs incubation. The wild type NY-EM hydrolyzed 68% of sucrose and hence, only 32% of sucrose remains in the medium after 24hrs incubation. This result highlights that the NY-EM2 strain also dramatically lost the ability to hydrolyze the sucrose for its growth and makes 35% more sucrose available for bioconversion in to trehalulose by sucrose isomerase. The results of this study are depicted in Fig.3.
In the second instance, the uptake and utilization of sucrose, individually and in combination with glucose and fructose was studied. Wild type strains (NY-EM and NY-YM) and the recombinant strains (NY-EM2 and NY-YM2) were grown in synthetic growth media containing 20 g/L sucrose alone or 20 g/L sucrose supplemented with 20 g/L glucose or fructose. After 24 hrs of growth the residual sucrose was analyzed by HPLC analysis.
Both NY-YM2 and NY-EM2 strains show the presence of residual sucrose in the media after 24 hrs of incubation due to their inability to hydrolyze the sucrose, while the wild type strain was found to be hydrolyzing the sucrose completely. When glucose or fructose (hydrolysis products of sucrose) is supplemented in the synthetic growth media the hydrolysis of sucrose is reduced in wild type strain itself since the presence of glucose can regulate the invertase enzymes expression but both NY-YM2 and NY-EM2 strain show better accumulation of sucrose compared to wild type strain.
This result highlights that the glucose can be used as carbon source for growth of NY -YM2 and NY-EM2 strains for whole cell biocatalyst preparation. Glucose can also be used while bioconversion of sucrose in to trehalulose is being done by the recombinant strains.
Further, it was observed that the NY-YM2 and NY-EM2 strains grow slowly compared to their wild type strains in growth media containing sucrose as sole carbon source due to their inability to hydrolyze sucrose, whereas the growth behavior of NY-YM2 and NY-EM2 stains are similar to wild type strains when grown with glucose.
When glucose or fmctose was supplemented with sucrose the wild type strain showed reduced hydrolysis of sucrose due to regulated expression of invertase gene expression by glucose. However, the double mutant strain showed remarkable reduction in hydrolysis of sucrose compared to the respective wild type strains. The results of the studies are depicted in Fig.4.
In the third instance, the residual invertase activity of NY-EM2 and NY-YM2 strains compared to the respective wild type strains was studied. The cells were incubated with 9.5 g/L sucrose in sucrose isomerase assay buffer at 30°C for up to 12 hrs and samples were analyzed for residual sucrose after formation of glucose and fructose (not shown) by action of residual invertase activity.
The mutant strains were able to grow identical to their wild type strain when grown in presence of glucose or fructose. Sucrose remained unaltered up to 8hrs when incubated with double mutant strains whereas the wild type strain exhibited that sucrose was getting depleted gradually. Approximately 70 - 75 % sucrose remained unaltered when incubated with double mutant strain(s) for 24 - 48 hrs whereas sucrose was completely depleted by wild type strain at similar conditions. Both NY-YM2 and NY-EM2 strains show high amount of residual sucrose in the sucrose isomerase assay buffer at optimum temperature even after 12 hrs of incubation, whereas the sucrose is depleted when incubated with wild type strain due presence of high invertase activity.
This result highlights that the NY-YM2 and NY-EM2 strains are very suitable host strains for the development of recombinant strains for production of cell surface displayed sucrose isomerase, which can be used as whole cell biocatalyst for bioconversion of sucrose in to trehalulose. The results of the studies are depicted in Fig.5.
Example 6: Development of recombinant yeast strains by transformation with recombinant gene constructs
Both recombinant yeast strains developed in this invention NY-YM2 and NY-EM2 and respective wild type strains NY - YM and NY -EM were transformed with recombinant constructs pGH-SI_R3 and pGL-SI_R3, respectively. The strains were grown in YEPD broth and supplemented with 2% glucose and the cells were treated with ice cold sorbitol to prepare electrocompetent cells. The recombinant constructs pGH-SI_R3 and pGL-SI_R3 were transformed in to electrocompetent cells by standard electroporation method. The strains transformed with pGH-SI_R3were selected on SD-Uraplates and the strains transformed with pGL-SI_R3were selected on SD-Trp or at 30°C.Transformed strains NY-YM(pGH-SI_R3), NY- YM2 (pGH-SI_R3), NY-EM (pGL-SI_R3), and NY-EM2 (pGL-SI_R3) were verified for the presence of plasmid by subsequent selections and restriction digestion analysis.
For verification of constitutive expression of CSD-SIase in the modified recombinant strain NY-YM2(pGH-SI_R3) and control recombinant strain NY-YM(pGH-SI_R3) were grown in Synthetic Dropout Medium without uracil.
Similarly, for verification of inducible expression CSD-SIase in the modified recombinant strain NY-EM2 (pGL-SI_R3) and control recombinant strain NY-EM (pGL-SI_R3) were grown in Synthetic Dropout Media without tryptophan. Cells were grown in SD Trp- medium with 2% glucose up to late logarithmic phase and induced by addition of 2% galactose for production of CSD-SIase.
Example 7: Microscopy of immunofluorescence labelled yeast cells
For immunofluorescence analysis, the yeast strains NY-EM2 (pGL-empty), NY-EM2 (pGL-SI_R3), NY-YM2 (pGH-empty) and NY-YM2 (pGH-SI_R3) were collected after induction or constitutive expression of CSD-SIase, respectively.
The cells were washed with phosphate buffered saline (PBS) and treated with 3.7 % formaldehyde in PBS at room temperature for 15 min. After fixation, the cells were washed with PBS and attached to a polylysine coated slide. Fixed cells were coated with 5% bovine serum albumin (BSA) in PBS at room temperature for 20 minutes in order to avoid non-specific binding of antibodies. Coated cells were washed with PBS containing 1% BSA (PBS-B) and incubated with anti-sucrose isomerase primary antibody developed in rabbit in PBS-B for 30 min at room temperature. Antibody bound cells were washed thrice in PBS-B and incubated with
biotinylated anti-rabbit secondary antibody for another 30-60 minutes at room temperature. The cells were washed with PBS-B for thrice to remove the unbound antibodies and incubated with streptavidin (AlexaFluor488, Invitrogen) in PBS at room temperature for 30-60 minutes. The cells were washed and a drop of DAPI in an aqueous mounting medium was added for the staining the DNA of mounted cells and for fixing the cover-slip.
Immunofluorescence analysis was performed using excitation which gives a Cyan-Green color at absorbance 495nm and excitation at 5l9nm wavelength for Alexa-488 staining and 345nm absorbance spectra and 455nm emission spectra for DAPI staining.
Images were taken on inverted Nikon Eclipse 50i fluorescent microscope under 200 x magnifications and analyzed.
The results of the microscopy of immunofluorescence-labeled yeast cells are depicted in Figure 6. Lane 1 and 2 depict control strain and strain expressing CSD-SIase constitutively, respectively. Lane 3 and 4 depict uninduced strain carrying inducible construct and induced strain for expression of CSD-SIase, respectively. Cell surface displayed GPI-fused Slase were detected in the Ist row by using anti-Sucrose isomerase antibody produced in rabbit, biotinylated goat anti -rabbit IgG and Streptavidin Alexa Fluor® 488 which is a biotin-binding protein (streptavidin) covalently attached to a fluorescent label. DAPI stain was used to visualize the nucleus in the 2nd row. The normal images of the cells were viewed by Nomarski differential interference contrast microscopy in the 4th row. The images were taken with an inverted Nikon Eclipse 50i fluorescent microscope under 200x magnification using different filters. Overlay of both Alexa and DAPI staining in the 3rd row shows the number of yeast cells stained with cell surface displayed recombinant sucrose isomerase.
Almost all recombinant NY-YM2 (pGH-SI_R3) yeast strains displaying the modified sucrose isomerase on their cell surface is confirmed by immunofluoresence in Lane2, whereas the control NY-YM2 (pGH-empty) yeast strains do not display any modified sucrose isomerase (lane 1, column 1).
For the induced expression of GPI-SIase in NY-EM2 (pGH-SI_R3), more than 50% cells are displaying the modified sucrose isomerase on their cell surface as depicted in Lane 4, whereas the control NY-YM2 (pGH-empty) yeast strains do not display any modified sucrose isomerase (lane 3, column 1).
Example 8: Immunoblot analysis from different fractions of cell lysate
For immunoblot analysis the yeast strains NY-EM (pGL-SI_R3), NY-EM2 (pGL-SI_R3), NY-YM (pGH-SI_R3) and NY-YM2 (pGH-SI_R3) were collected after induction or constitutive expression of CSD-SIase, respectively. Equal amount of cells were lysed in lysis buffer (50 mM Tris-HCl pH 8.0, 1% DMSO, 50-200 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 pg/ml leupeptin, 1 pg/ml pepstatin A) using acid washed glass beads. The cell lysates were subject to SDS-PAGE and Western blot analysis. Anti-sucrose isomerase antibody developed in rabbit was used as primary antibody and goat anti rabbit AP-conjugate (alkaline phosphatase conjugate) was used as secondary antibody. The blots were developed using BCIP/NBT (5-bromo-4-chloro-3- indolylphosphate/nitro blue tetrazolium) substrate for the detection.
The activity of CSD-SIase was examined by incubating cells with 500mM sucrose solution in 20 mM citrate acetate buffer (pH 6.5) with I OmM CaCFas an additive and the reaction mixture was incubated at l2°C for 8 hrs. The enzymatic reaction was stopped by deactivating the enzyme at 95 °C in a boiling water bath for 10 min.
The results of the immunoblot analysis is depicted in Fig. 7, which shows the expression profile of CSD-SIase by immunoblot analysis from different fractions of cell lysate from constitutive or inducible expression strains. Equal amount of cells were lysed and the whole cell lysate (lane 1 and 5), supernatant (lane 2 and 6) and pellet (lane 3 and 7) fractions were separated on SDS-PAGE and transferred to nitrocellulose membrane for Western blot analysis. Rabbit anti-SIase antibody and Goat anti-rabbit secondary antibody were used for detection. Lane 8 depicts protein molecular weight marker and Lane 9 depicts purified recombinant Slase.
Identity of sucrose isomerase displayed on the yeast cell wall was confirmed by Western blot analysis (in lane 5 - 7), whereas there is no signal for sucrose isomerase in control strain (lane 1 - 3). Moreover, the cell membrane fraction (lane 7) showed that the majority of sucrose isomerase is present on the cell wall.
Example 9: Fermentation kinetics and cell surface display for recombinant transformed strains exhibiting constitutive expression
Fermentation of yeast strain NY-YM2 (pGH-SI_R3) was carried out in defined media without uracil at 30°C for 42 hrs. Samples were collected at different time points and tested for growth and CSD-SIase activity. The enzyme assay was carried out in 20 mM citrate acetate buffer (pH 6.5) with 10 mM CaCk, 8.5% sucrose solution and 5 OD units of CSD-SIase cells (1
OD6OO is roughly 3x 107 cells/ml). The reaction mixture was incubated at l2°C for 4 hrs. The enzymatic reaction was stopped by deactivating the enzyme at 95°C in a boiling water bath for 10 min. The reaction mixtures were subject to HPLC analysis to confirm the residual substrate and product formation.
Fig. 8 shows the fermentation kinetics and cell surface displayed Slase activity of recombinant strain producing CSD-SIase by constitutive expression strain NY-YM2 (pGH- SI_R3).
This result highlights that the NY-YM2 (pGH-SI_R3) strain is constitutively producing modified sucrose isomerase (GPI-SIase), which is GPI anchor protein fused to sucrose isomerase. The produced GPI-SIase is subsequently displayed on the cell surface of the NY- YM2 (pGH-SI_R3) strain which enabled it to convert sucrose in to trehalulose when cells were tested for sucrose isomerase activity throughout the fermentation.
Example 10: Fermentation kinetics and cell surface display for recombinant transformed strains exhibiting inducible expression
Fermentation of NY-EM2 (pGL-SI_R3) yeast strain was carried out in defined media without uracil at 30 °C for 42 hrs. Samples were collected at different time points and tested for growth and CSD-SIase activity. The enzyme assay was carried out in 100 mM citrate acetate (pH 6.5) with 150 mM NaCb, 8.5% sucrose solution and 5 OD units of CSD-SIase cells (1 OD6oo is roughly 3x 107 cells/ml). The reaction mixture was incubated at l4°C for 4 hrs. The enzymatic reaction was stopped by deactivating the enzyme at 95 °C in a boiling water bath for 10 min. The reaction mixtures were subject to HPLC analysis to confirm the residual substrate and product formation with appropriate standards.
Fig. 9 shows the fermentation kinetics and cell surface displayed sucrose isomerase activity of recombinant strain producing CSD-SIase by inducible expression strain NY-EM2 (pGL-SI_R3).
This result highlights that upon induction the NY-EM2 (pGL-SI_R3) strain starts producing modified sucrose isomerase (GPI-SIase), which is GPI anchor protein fused to sucrose isomerase. The produced GPI-SIase is subsequently displayed on the cell surface of the NY- EM2 (pGL-SI_R3) strain and was able to convert sucrose in to trehalulose when the 34 - 70 hrs fermentation cells were tested for sucrose isomerase activity.
Example 11: Immunoblot analysis of samples collected from constitutive or inducible expression strains at different fermentation times
Fig. 10 shows the expression profile of CSD-SIase by immunoblot analysis from samples collected from constitutive [NY-YM2 (pGH-SI)] or inducible expression [NY-EM2 (pGL-SI)] strains at different fermentation time points. Equal amount of cells were collected at different fermentation time points and analyzed for the expression profile of CSD-SIase. The cells were lysed using glass beads in yeast cell lysis buffer and total cell lysate was separated on 10 % SDS- PAGE and were analyzed by Western blot. Rabbit anti-sucrose isomerase antibody and goat anti-rabbit secondary antibody was used for detection. The abbreviations used in the figure are C for purified Slase as positive control, M for protein molecular weight marker, kDa for Kilo Dalton and Ab for Antibody.
This result shows the presence and identity of sucrose isomerase on the cell surface of both NY-YM2 (pGL-SI_R3) and NY-EM2 (pGL-SI_R3) strains as shown in figure A and B, respectively. Sucrose isomerase is produced constitutively from the beginning in NY-YM2 (pGH-SI_R3), whereas in NY-EM2 (pGL-SI_R3) it is produced only after induction.
Example 12: Production of whole cell biocatalysts with cell surface display
For large scale production of CSD-SIase, the cells were grown in defined media comprised of base medium components (10 g/L (NH4)2S04, 10 g/L KH2P04, 0.5 g/L CaCl2.2FbO, 0.5 g/L NaCb and 3 g/L MgSo4.7H20), trace elements (278 mg/L FeS04.7H20, 288 mg/L ZnS04.7H20, 80 mg/L CuS04.5H20, 242 mg/L Na2Mo04.2H20, 238 mg/L C0CI2.6H2O and 198 mg/L MnCbAFLO), vitamins (10 mg/L biotin and 120 mg/L Thiamine HC1), liquor ammonia and 1% yeast extract, which was used as an alkali and nitrogen source. The temperature of the fermentation was maintained at 28 °C at a pH 5.5 and oxygen level was maintained not less than 40%, throughout the fermentation. The fermentation process for constitutive production of CSD-SIase at 2L scale was carried out for 24 - 48 hrs and which yields 40 - 80 g/L biomass. For production of inducible CSD-SIase strain the cells were grown in defined media with 10 - 20 % glucose for generation of biomass and after depletion of glucose the cells were induced with 2 - 5% galactose for production of CSD-SIase. At each time points the cells were collected and monitored for the expression of CSD-SIase activity. The cells were collected after fermentation and washed with phosphate saline buffer and used as whole cell biocatalyst for production of trehalulose.
Example 13: Production of trehalulose using CSD-SIase cell
For production of trehalulose from sucrose, CSD-SIase cells produced in previous example was used as whole cell biocatalyst. The optimization of process parameters for the production of trehalulose was carried out with varying pH and temperature, which were used for the production of trehalulose.
Production of trehalulose from sucrose was carried out by using 5-50 OD units more precisely, 10 OD units of CSD-SIase cells (1 OD6oo is roughly 3 x 107 cells/ml). The cells were contacted with varying concentration of sucrose, more particularly 10%, 20%, 30%, 40% and 45% sucrose solution, in 20 mM citrate acetate buffer (pH 6.5) with 10 mM CaCFas an additive atl2°C for 12-24 hrs.
After bioconversion of sucrose to trehalulose using CSD-SIase, the sugar solution was subjected to cation and anion exchange resins to remove salt and ions present in buffer solutions. Furthermore, the sugar solution was concentrated using rotary vacuum evaporator system and subsequently passed through a column packed with activated charcoal, in order to remove the color. The purity of the product was analyzed by HPLC and ions contaminations were analyzed in ion chromatography.
Physico-chemical properties and purity of the product were checked by using standard techniques to confirm the safety aspects of produced trehalulose in this process. The percentage of bioconversion of sucrose to trehalulose was about 50-60 %. From total produced sugars, trehalulose was found to be 90-95 % with trace amounts of isomaltulose, glucose and fructose. Example 14: Product formation kinetics using different amount of CSD-SIase cells
After fermentation of CSD-SIase expressing strains, the cells were harvested and used for sucrose isomerase activity analysis. The enzyme assay was carried out using 1 OD, 3 OD and 5 OD units of CSD-SIase cells (1 OD6oo is roughly 3 x 107 cells/ml) in 20 mM citrate acetate buffer (pH 6.5) with 10 mM CaCF and 8.5% sucrose solution. The reaction mixture was incubated at l2°C for 8 hrs. The enzymatic reaction was stopped by deactivating the enzyme at 95°C in a boiling water bath for 10 min. The reaction mixtures were subjected to HPLC analysis to confirm the residual substrate and product formation with appropriate standards.
Fig. 11 shows the product formation kinetics using different amount of CSD-SIase cells. For this experiment, the recombinant strain exhibiting constitutive expression was used. This result shows the product formation kinetics by different amount of CSD-SIase whole cell
biocatalyst. The results show that the production of trehalulose increases proportionately related to the amount of CSD-SIase cells used in given reaction time with same amount of substrate. When 5 OD cells were used, 11% to 45% product is formed between 0.5 to 24 hrs of reaction time, while only 6% to 19% product is formed in the same time when used 1 OD cells are used. Therefore, amount of whole cell biocatalyst can be increased up to 50 OD units for the bioconversion reaction for efficient conversion of sucrose in to trehalulose.
Example 15: Product formation kinetics using different amounts of sucrose
After fermentation of CSD-SIase expressing strains, the cells were harvested and used for analysis of product formation kinetics by CSD-SIase cells. The enzyme assay was carried out in 20 mM sodium acetate (pH 6.5) with 10 mM CaCb as an additive with different concentration of substrate and 5 OD units of CSD-SIase (1 OD6oo is roughly 3 x 107 cells/ml). For this experiment, the recombinant strain exhibiting constitutive expression was used. The reaction mixture was incubated at l2°C for 8 hrs. The enzymatic reaction was stopped by deactivating the enzyme at 95°C in a boiling water bath for 10 min. The reaction mixtures were subjected to HPLC analysis to confirm the residual substrate and product formation with appropriate standards.
Fig. 12 shows the product formation kinetics using different amount of sucrose as substrate with CSD-SIase.
This result shows the product formation kinetics with different amount of substrate for bioconversion. The results shows that the production of trehalulose increases proportionately to the amount of substrate used in given reaction time with same amount of CSD-SIase cells. When 150 g/L, 300 g/L and 450 g/L sucrose were used, 49 g/L, 120 g/L and 189 g/L trehalulose were produced respectively when contacted with 5 OD cells for 16 hrs. Therefore, amount of substrate can be increased up to 45% with appropriate whole cell biocatalyst and reaction time for efficient conversion of sucrose in to trehalulose.
Example 16: Chromatogram of bioconversion of sucrose to trehalulose by recombinant strain exhibiting constitutive expression
HPLC analysis of substrate (sucrose) blank, bioconversion of substrate in to products by recombinant strain and substrate incubated with wild type strain were performed. Substrate and products were identified with appropriate standards. Fig. 13 depicts the results of HPLC analysis of bioconversion of sucrose into trehalulose by CSD-SIase strain.
Figure A presents the chromatogram of blank substrate (sucrose). Chromatograms of bioconversion performed using NY-YM2 (pGH-SI_R3) and NY-YM (pGH-SI_R3) strains are shown as figure B and C, respectively.
In NY-YM (pGH-SI_R3) strain constitutively producing CSD-SIase is able convert sucrose in to trehalulose but besides the formation of trehalulose the fructose and glucose were also formed due the invertase activity of the yeast strain S. cerevisiae. However, the NY-YM2 (pGH-SI_R3) strain show dramatic decrease in fructose and glucose level as the major sucrose invertase and symporter, SUC2 and AGT1 are deleted in this strain. Hence the sucrose (substrate) was mainly converted to trehalulose by CSD-SIase.
Example 17: Bioconversion kinetics of CSD-SIase produced by recombinant strain exhibiting constitutive expression
CSD-SIase yeast cells [NY-YM2 (pGH-SI_R3)] were incubated with 8.2% sucrose in 10 mM calcium acetate (pH 6.5) with 150 mM NaCFand incubated at l2°C for different time points. The enzymatic reaction was stopped by deactivating the enzyme at 95°C in a boiling water bath for 10 min. The reaction mixtures were subject to HPLC analysis to confirm the residual substrate and product formation with appropriate standards.
This result shows the bioconversion kinetics of 5 OD of NY-YM2 (pGL-SI_R3) cells when contacted with 8.5% sucrose. Within 2.5 hrs, 1% trehalulose is formed and increased up to 2.2% when incubated for 4 hrs. Therefore, amount of whole cell biocatalyst up to 40-50 OD cells (as shown in Fig. 11) and substrate up to 45 - 50% (as shown in Fig. 12) in combination with reaction time up to 24 to 48 hrs can be used for efficient conversion of sucrose in to trehalulose.
Fig. 14 depicts the bioconversion kinetics of CSD-SIase produced by constitutive expression strain [NY -YM2 (pGH-SI)] .
Example 18: Bioconversion kinetics of CSD-SIase produced by recombinant strain exhibiting inducible expression
CSD-SIase yeast cells [NY-EM2 (pGL-SI_R3)] were incubated with 8.2% sucrose in 10 mM calcium acetate (pH 6.5) with 150 mM NaCFand incubated at l2°C for different time points. The enzymatic reaction was stopped by deactivating the enzyme at 95°C in a boiling water bath for 10 min. The reaction mixtures were subject to HPLC analysis to confirm the residual substrate and product formation with appropriate standards. Fig. 15 shows the
bioconversion kinetics of CSD-SIase produced by inducible expression strain [NY-EM2 (pGL- SI_R3)].
This result shows the bioconversion kinetics of 5 OD of NY-EM2 (pGL-SI_R3) cells when contacted with 8.2% sucrose. Within 2 hrs,2% trehalulose is formed and increased up to 3.2% when incubated for 4 hrs.
Therefore, amount of whole cell biocatalyst up to 40-50 OD cells (as shown in Fig. 11) and substrate up to 45-50% (as shown in Fig. 12) in combination with reaction time up to 24 hrs can be used for efficient conversion of sucrose in to trehalulose.
Example 19: Temperature optima profile of CSD-SIase and native enzyme
Temperature optimum was determined by incubating the reaction mixture with constitutive produced CSD-SIaseand the respective native Slase at various temperatures ranging from l0°C - 70°C in 10 mM calcium acetate (pH 6.5) with 150 mM NaCEand incubated for 12 hrs. Enzyme activities were determined at pH 6.5 and the relative activity was calculated by assuming that the activity observed at 30°C for CSD-SIase and 40°C for native Slase was 100%. Fig. 16 shows the temperature optima profiles of CSD-SIase and native Slase.
This result shows the optimum temperature for bioconversion of sucrose in to trehalulose by CSD-SIase cells or whole cell biocatalyst is 30°C whereas the native enzyme has temperature optima at 35°C. Moreover, the CSD-SIase cells or whole cell biocatalyst remains active with slight decrease at lower temperatures as well which might me an advantage to operate the bioconversion at lower temperatures.
Example 20: pH profile of CSD-SIase and native enzyme
The pH optimum was determined by incubating the constitutively produced CSD-SIase and native Slase with sucrose in assay buffer with different pH and 10 mM CaCb as an additive. Enzyme activities were measured at l2°C and the relative activity was calculated by assuming that the activity observed at pH 6.5 was 100%. Fig. 17 shows the pH profiles of CSD-SIase and native Slase.
This result shows the optimum pH for bioconversion of sucrose in to trehalulose by CSD- SIase cells or whole cell biocatalyst is 6.5which is similar to that of the native enzyme. Moreover, the CSD-SIase cells or whole cell biocatalyst remains active with slight decrease at lower pH as well which might be an advantage to operate the bioconversion at decreased pH conditions.
Example 21: Residual activity of CSD-SIase enzyme compared to native Slase enzyme
The stability of CSD-SIase were checked by incubating the CSD-SIase cells in sucrose isomerase buffer at optimum temperature and cells were collected at different time points for residual CSD-SIase activity analysis. The enzyme assay was carried out in 10 mM calcium acetate (pH 6.5) with 150 mM NaCh and 8.5% sucrose solution and 5 OD units of CSD-SIase cells (1 OD6OO is roughly 3 x 107 cells/ml).
For this experiment, the recombinant strain exhibiting constitutive expression was used. Fig. 18 shows the residual activity of CSD-SIase enzymes compared to native Slase enzyme. This result shows that the CSD-SIase cells or whole cell biocatalyst retains 80%, 70%, 55% and 50% of its activity after 24 hrs, 48 hrs, 96 hrs and 120 hrs respectively in optimum reaction condition, which is slightly lower than the native free sucrose isomerase activity.
However, the stability of native sucrose isomerase falls rapidly after 72 hrs whereas the CSD-SIase activity retains stability for a longer period. Therefore, the CSD-SIase has almost similar stability to the native enzyme for continuous bioconversion.
Claims
1. A recombinant host cell, wherein the sucrose hydrolyzing genes of the host cell have been deleted and the host cell comprises a fusion protein encoding gene comprising the nucleotide sequence of SEQ ID NO: 1.
2. The recombinant host cell as claimed in claim 1 , wherein the host cell is Saccharomyces cerevisiae.
3. The recombinant host cell as claimed in claim 1, wherein the sucrose hydrolyzing genes are selected from a group comprising SUC2 gene and AGT1 gene.
4. The recombinant host cell as claimed in claim 1 , wherein the host cell is selected from a group comprising MTCC 5985 and MTCC 5987.
5. An expression cassette, comprising:
a. a fusion protein encoding gene comprising the nucleotide sequence of SEQ ID NO: 1, wherein the fusion protein is sucrose isomerase fused to C -terminus of a cell surface anchor protein;
b. a constitutive or an inducible promoter sequence which is operably linked to the fusion protein encoding gene; and
c. a terminator sequence.
6. The expression cassette as claimed in claim 5, wherein the constitutive promoter comprises the nucleotide sequence of SEQ ID NO: 2, the inducible promoter comprises the nucleotide sequence of SEQ ID NO: 3 and the terminator sequence is chosen from a group comprising a GAPDH terminator comprising the nucleotide sequence of SEQ ID NO: 4 and an Alpha Factor terminator comprising the nucleotide sequence of SEQ ID NO: 5.
7. A polypeptide comprising a polypeptide sequence of SEQ ID NO: 6, wherein the polypeptide is sucrose isomerase fused to C-terminus of a cell surface anchor protein.
8. A vector comprising the expression cassette as claimed in claim 5.
9. The vector as claimed in claim 8, further comprising a yeast replication origin, a yeast selection marker gene, a bacterial replication origin and a bacterial selection marker gene.
10. The vector as claimed in claim 9, wherein the yeast replication origin is selected from a group comprising a yeast 2-micron sequence and a yeast centromere sequence.
11. The vector as claimed in claim 9, wherein the bacterial selection marker gene is an ampicillin resistance gene and the yeast selection marker gene is selected from a group comprising URA3 gene and TRP1 gene.
12. A recombinant Saccharomyces cerevisiae host cell, wherein the SUC2 and AGT1 genes have been deleted.
13. The recombinant Saccharomyces cerevisiae host cell as claimed in claim 12, comprising the vector as claimed in claim 8.
14. A process for development of a recombinant Saccharomyces cerevisiae host cell exhibiting high sucrose isomerase activity, said process comprising the steps of:
a. deleting SUC2 and AGT1 genes in the host cell using an inducible excision system; and
b. transforming the host cell with a vector of claim 8.
15. The process as claimed in claim 14, wherein the inducible excision system is cre-lox excision system using a marker selected from a group comprising kanamycin resistance gene and phleomycin resistance gene.
16. A process for production of trehalulose from sucrose, said process comprising the steps of:
a. culturing the recombinant Saccharomyces cerevisiae host cells as claimed in claim 13 in defined media, wherein the culture medium has pH ranging between 4 to 6.5 and temperature maintained between l5°C to 30°C;
b. contacting the recombinant host cells with sucrose solution, wherein the sucrose solution comprises 10% to 45% (w/v) sucrose; and
c. harvesting trehalulose from the solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2018/051736 WO2019175635A1 (en) | 2018-03-15 | 2018-03-15 | Novel whole-cell biocatalyst for the production of trehalulose |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2018/051736 WO2019175635A1 (en) | 2018-03-15 | 2018-03-15 | Novel whole-cell biocatalyst for the production of trehalulose |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019175635A1 true WO2019175635A1 (en) | 2019-09-19 |
Family
ID=67906488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2018/051736 WO2019175635A1 (en) | 2018-03-15 | 2018-03-15 | Novel whole-cell biocatalyst for the production of trehalulose |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019175635A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013156940A1 (en) * | 2012-04-17 | 2013-10-24 | Agtive Bio-Sciences Private Limited | A method of production of rare disaccharides |
US20170204394A1 (en) * | 2014-05-30 | 2017-07-20 | Braskem S.A. | Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same |
-
2018
- 2018-03-15 WO PCT/IB2018/051736 patent/WO2019175635A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013156940A1 (en) * | 2012-04-17 | 2013-10-24 | Agtive Bio-Sciences Private Limited | A method of production of rare disaccharides |
US20170204394A1 (en) * | 2014-05-30 | 2017-07-20 | Braskem S.A. | Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same |
Non-Patent Citations (2)
Title |
---|
GIL-YONG LEE ET AL.: "Isomaltulose production via yeast surface display of sucrose isomerase from Enterobacter sp. FMB-1 on Saccharomyces cerevisiae", BIORESOURCE TECHNOLOGY, vol. 102, 2011, pages 9179 - 9184, XP028276325 * |
MARQUES WL ET AL.: "Elimination of sucrose transport and hydrolysis in Saccharomyces cerevisiae: a platform strain for engineering sucrose metabolism", FEMS YEAST RESEARCH, vol. 17, no. 1, 1 January 2017 (2017-01-01), pages 1 - 11, XP055635132 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5024941A (en) | Expression and secretion vector for yeast containing a glucoamylase signal sequence | |
Liu et al. | The Saccharomyces cerevisiae genes (CMP1 and CMP2) encoding calmodulin-binding proteins homologous to the catalytic subunit of mammalian protein phosphatase 2B | |
US4943529A (en) | Kluyveromyces as a host strain | |
EP2106447B1 (en) | Method for methanol independent induction from methanol inducible promoters in pichia | |
US20100297738A1 (en) | Expression system | |
JP5562647B2 (en) | Genetically modified yeast for the production of homogeneous glycoproteins | |
EP1975237B1 (en) | Beta-fructofuranosidase variants and uses thereof | |
JP2012105652A (en) | Process for producing protein with reduction of acidic sugar chain and glycoprotein produced thereby | |
KR20140015137A (en) | Methods for the production of recombinant proteins with improved secretion efficiencies | |
MXPA03004853A (en) | Methods and compositions for highly efficient production of heterologous proteins in yeast. | |
Sun-Wada et al. | Functional expression of the human UDP-galactose transporters in the yeast Saccharomyces cerevisiae | |
US5470971A (en) | Stress-induced proteins, genes coding therefor, transformed cells of organisms, methods and applications | |
US7655449B2 (en) | β-fructofuranosidase variants | |
CN101473035B (en) | Method for reinforcing secretion efficiency of recombination exogenous protein in sprout fungi expression system | |
KR100576409B1 (en) | Beta-fructofuranosidase and its genes | |
WO2019175635A1 (en) | Novel whole-cell biocatalyst for the production of trehalulose | |
WO2019175634A1 (en) | Novel whole-cell biocatalyst for the production of isomaltulose | |
EP4455277A1 (en) | Production of rebaudioside | |
JP5148879B2 (en) | Method for clarifying protein fusion factor (TFP) for secretion of difficult-to-express protein, method for producing protein fusion factor (TFP) library, and method for recombinant production of difficult-to-express protein | |
KR100915670B1 (en) | A novel YlMPO1 gene derived from Yarrowia lipolytica and a process for preparing a glycoprotein not being mannosylphosphorylated by using a mutated Yarrowia lipolytica in which YlMPO1 gene is disrupted | |
Kühn et al. | A novel zinc finger protein encoded by a couch potato homologue from Solanum tuberosum enables a sucrose transport-deficient yeast strain to grow on sucrose | |
US7198932B1 (en) | Gdp-4-keto-6-deoxy-d-mannose-3,5-epimerase-4-reductase gene derived from arabidopsis thaliana | |
KR20050077399A (en) | Transformed saccharomyces cerevisiae and production method of lk8 protein using the same | |
JP2715000B2 (en) | Expression of protein sweetener in yeast | |
KR100977446B1 (en) | A novel gene of Hansenula polymorpha that regulates secretory stress response and a method of increasing the secretory expression efficiency of recombinant protein using the gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18910131 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18910131 Country of ref document: EP Kind code of ref document: A1 |